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Abstract
Tobacco smokers are at increased risk for the development and progression of chronic
pain, and smokers with co-occurring pain tend to report greater difficulty and less confidence in
quitting. Smokers in pain face unique cessation challenges and may benefit from tailored
interventions that address smoking in the context of pain. This pilot study is the first to test the
effects of an intervention tailored for smokers with co-occurring pain on motivation to quit and
engage cessation treatment. Smokers with chronic pain (N = 76, 57.9% Female, 52.6% White,
Mcpd = 17.64) were randomly assigned to either the tailored or control intervention. Results
indicated that the tailored intervention (vs. control) increased knowledge of pain-smoking
interrelations, motivation to quit smoking, desire to quit, and expected success in quitting (ps <
.01). Participants who received the tailored intervention were also more likely to accept
information about available smoking cessation treatments (p = .015), and to report interest (p =
.006) and intention to engage treatment in the next month (p = .003). Effects of the tailored
intervention on desire to quit and willingness to learn about cessation treatments were mediated
by increased knowledge of pain-smoking interrelations. At one-month follow-up, treatment gains
in knowledge of pain-smoking interrelations were maintained (p = .009), and participants who
received the tailored intervention were more likely to report having subsequently talked to their
doctor about smoking (p = .034). These data support the notion that smokers with co-occurring
pain may benefit from interventions that have been tailored to address tobacco smoking in the
context of pain. Collectively, these findings suggest that smokers with co-occurring pain may
become more motivated to quit and engage cessation treatment as they become aware of how
continued smoking may be incongruent with their desired pain outcomes.
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1
Increasing Cessation Motivation and Treatment Engagement among Smokers in Pain
Tobacco use remains the leading preventable cause of mortality in the United States
(US), accounting for an estimated 448,000 deaths and nearly $289 billion in health-related
economic losses annually (DHHS, 2014). Despite the known health risks, including multiple
forms of cancer, cardiovascular diseases, and respiratory diseases (DHHS, 2004), nearly 36
million American adults (15.1%) continue to smoke cigarettes (Jamal et al., 2016). Like
smoking, pain is a critical national health problem that affects over 100 million adults at an
annual cost in excess of $560 billion (IOM, 2011). Estimates derived from nationallyrepresentative and clinical pain samples suggest that the prevalence of tobacco smoking among
persons with co-occurring pain may be greater than twice the rate observed in the general
population (28%-68%; Goesling, Brummett, & Hassett, 2012; Michna et al., 2004; Orhurhu,
Pittelkow, & Hooten, 2015; Patterson et al., 2012).
Despite recent declines in smoking prevalence among US adults, there remain subgroups
of smokers that evince substantially greater smoking prevalence and tobacco-related health
disparities (Borrelli, 2010). The hardening hypothesis posits that remaining smokers may be
“burdened” by characteristics that make continuous abstinence more difficult (Hughes &
Brandon, 2003) or recalcitrant to quitting (Augustson & Marcus, 2004; Irvin & Brandon, 2000).
A growing body of evidence indicates that interrelations between pain and smoking are
reciprocal in nature, ultimately resulting in greater pain and the maintenance of smoking (e.g.,
Ditre, Brandon, Zale, & Meagher, 2011; Zale, Maisto, & Ditre, 2016). As such, smokers in pain
likely represent an important subgroup, which faces unique smoking-related health disparities
and may benefit from tailored interventions that address smoking in the context of pain (Ditre et
al., 2011; Zale, Ditre, Dorfman, Heckman, & Brandon, 2014).
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Several converging lines of evidence indicate that tobacco smoking contributes to the
onset and progression of chronic pain and interferes with pain treatment. First, smoking has been
identified as a unique risk factor in the development of rheumatoid arthritis (DHHS, 2014) and
chronic low-back pain (Shiri, Karppinen, Leino-Arjas, Solovieva, & Viikari-Juntura, 2010), and
smoking has been associated with the prevalence/severity of numerous other painful conditions
(e.g., Aamodt, Stovner, Hagen, Brathen, & Zwart, 2006; Amin et al., 2007; Lee et al., 2010;
Patel et al., 2006; Winn, 2001). Among treatment-seeking pain patients, smokers consistently
report greater pain intensity and pain-related disability than nonsmokers (e.g., Hooten, Shi,
Gazelka, & Warner, 2011; Weingarten et al., 2008; Weingarten et al., 2009), and there is some
evidence that pain and disability may be even more pronounced among smokers who are more
dependent on tobacco (Hahn, Rayens, Kirsh, & Passik, 2006; Hooten, Shi, et al., 2011). Tobacco
smoking has been shown to decrease the efficacy of pharmacologic and surgical pain treatments
(e.g., Glassman et al., 2007; Harty & Veale, 2010), and smokers are less likely to complete
treatment for chronic pain than nonsmokers (Hooten, Townsend, Bruce, & Warner, 2009).
Smokers are also more likely to continue to experience pain-related distress and disability
following pain treatment (Fishbain et al., 2008; Hooten, Townsend, Bruce, Schmidt, et al., 2009).
A growing body of research further suggests that smokers with co-occurring pain face
unique challenges to smoking cessation. Experimental evidence indicates that the experience of
pain can increase urge to smoke and motivate smoking behavior (Ditre & Brandon, 2008; Ditre,
Heckman, Butts, & Brandon, 2010), episodes of increased pain have been shown to precede
bouts of cigarette smoking (Dhingra et al., 2013), and smokers with chronic pain consistently
endorse smoking in response to their pain (Jamison, Stetson, & Parris, 1991; Patterson et al.,
2012). Treatment-seeking pain patients have also identified distraction from physical pain and
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pain-related distress as a primary smoking motive (Aimer et al., 2015; Hooten, Vickers, et al.,
2011). With regard to smoking cessation, smokers with co-occurring pain report greater
difficulty and less confidence in quitting (Ditre, Langdon, Kosiba, Zale, & Zvolensky, 2015;
Zale et al., 2014) and may be less likely to achieve long-term smoking abstinence (Aigner et al.,
2017; Waldie, McGee, Reeder, & Poulton, 2008). Experimental pain reactivity has also been
shown to predict relapse to smoking (Nakajima & al'Absi, 2011), and greater pain-related
anxiety has been shown to predict early lapse and relapse to smoking in the context of a selfguided quit attempt (LaRowe, Langdon, Zvolensky, Zale, & Ditre, in press). Despite the
possibility that co-occurring pain may impede smoking cessation, there is some evidence that
smokers may experience clinically-meaningful reductions in pain severity after quitting (Behrend
et al., 2012).
Although more than 70% of all smokers endorse a desire to quit smoking (Fiore et al.,
2008), the vast majority (~90%) are not yet ready to make a serious cessation attempt (Herzog &
Blagg, 2007; Lichtenstein & Hollis, 1992; Pisinger, Jørgensen, Møller, Døssing, & Jørgensen,
2010). Behavioral and pharmacologic cessation therapies, which have been shown to more than
double quit rates, remain dramatically underutilized (Babb, Malarcher, Schauer, Asman, &
Jamal, 2017; CDC, 2011), and engaging smokers in evidence-based treatment has been identified
as a significant public health priority (USDHHS, 2010). Smokers who are not ready to engage an
abstinence-oriented treatment may be more amenable to interventions that are designed to
increase motivation and receptivity towards future cessation treatment (Drake & Mueser, 2000).
According to a phase-based framework for treating tobacco dependence, the process of
smoking cessation is comprised of four phases (i.e., Motivation, Precessation, Cessation,
Maintenance) that present unique opportunities for intervention (Baker et al., 2011). Smokers
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who are unwilling to make a serious quit attempt can be classified in the Motivation Phase of
smoking cessation. At the Motivation Phase, smokers should receive treatment designed to
increase the likelihood of future cessation attempts (Baker et al., 2016), and treatment effects
may be most appropriately assessed via self-report and behavioral indices of motivation to quit
(Baker et al., 2011). Prior research has demonstrated that psychoeducation regarding smokinghealth interactions may increase motivation to quit smoking (e.g., McCaul et al., 2006;
Zvolensky, Lejuez, Kahler, & Brown, 2003), and guidelines for brief motivational substance-use
interventions indicate that all patients should be educated about relations between substance use
and co-occurring medical conditions (SAMHSA, 2012).
Given emerging evidence of reciprocal relations between pain and smoking behavior,
researchers have suggested that smokers with co-occurring pain may benefit from tailored
interventions that address smoking in the context of pain (Ditre et al., 2011; Zale et al., 2014).
Smokers receiving treatment for chronic pain have indicated that they think providing messages
about pain and smoking (i.e., smoking may impede recovery) could be helpful in motivating
other patients to reduce their smoking (Kaye, Prabhakar, Fitzmaurice, & Kaye, 2012). A recent
pilot investigation of a smoking cessation treatment for pain patients found that an intensive 7session intervention, which was comprised of both individual and group cognitive behavioral
therapy, was efficacious in promoting smoking abstinence (Hooten et al., 2014). However, to
date, no studies have tested a tailored intervention for smokers in pain who are not yet ready to
engage a serious cessation attempt.
The objective of this study was to develop and pilot test a brief (i.e., single session)
intervention, which has been tailored to address smoking in the context of pain, for smokers with
chronic pain who are not ready to quit. Consistent with a phase-based approach (i.e., treatment at
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the Motivation Phase), the goals of the tailored intervention were to: (1) educate patients about
pain-smoking interrelations, (2) increase motivation to engage a serious quit attempt, and (3)
increase motivation to utilize available smoking cessation treatment. We conducted a pilot
randomized controlled trial of the brief tailored intervention versus the standard of care that is
recommended by US Department of Health and Human Services (DHHS) Clinical Practice
Guidelines for the Treatment of Tobacco Dependence (Fiore et al., 2008). We hypothesized that
smokers randomized to the tailored intervention (vs. control) would: (1) demonstrate greater
knowledge of pain-smoking interrelations, (2) self-report greater motivation to quit smoking, (3)
demonstrate a greater willingness to accept information about smoking cessation treatment, and
(4) self-report greater intention to utilize existing cessation services. We further hypothesized
that increased knowledge of pain-smoking interrelations would mediate effects of the tailored
intervention on motivation to quit smoking and engage cessation treatment. Finally, we
hypothesized treatment gains in knowledge of pain-smoking interrelations and motivation to quit
smoking would be maintained at one-month follow-up, and that smokers who received the
tailored intervention would be more likely to report having subsequently engaged smoking
cessation treatment.
Method
Participants
Participants were recruited from the local community via newspaper and internet
advertisements for a research study about smoking and chronic pain. Respondents were screened
by telephone for the following inclusion criteria: (1) between 18-65 years of age, (2) currently
smoking ≥ 10 cigarettes per day; (3) current self-reported moderate-very severe chronic pain; (4)
average pain intensity of at least 4/10 over the past three months. Given that we sought to recruit
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smokers who were not yet ready to quit, and therefore could be classified in the Motivation
Phase of smoking cessation, respondents were excluded if they reported a current active quit
attempt or use of treatment (i.e., pharmacological or behavioral) to help quit or cut down on
smoking. Participants who were determined to be eligible by phone screening were scheduled for
an in-person session.
Intervention Development
Development of the tailored intervention was informed by a growing empirical literature
on interrelations between pain and smoking (e.g., Ditre et al., 2011), theories of health behavior
change, SAMSHA recommendations for the development of brief interventions (SAMHSA,
2012), and Clinical Practice Guidelines for the Treatment of Tobacco Dependence (Fiore et al.,
2008). The Clinical Practice Guidelines recommend that smokers who are not ready to make a
quit attempt should receive brief interventions to promote motivation to quit. Common
components of evidence-based motivational smoking interventions include: (1) assessment of
smoking history, substance use, and mood; (2) identification of high risk smoking situations and
coping skills; (3) application of the FRAMES acronym (provide personalized feedback, advice to
quit, and a menu of strategies for quitting; emphasize personal responsibility for behavior
change; enhance self-efficacy; deliver the intervention in an empathic manner); and (4)
motivational enhancement (Emmons, 2007; Niaura & Shadel, 2007; Perkins, Conklin, & Levine,
2008). Motivational enhancement represents an adaptation of motivational interviewing that
incorporates personalized health-related feedback “that is intended to strengthen and consolidate
commitment to change and promote a sense of self-efficacy” (SAMHSA, 2013). Smokers are
more likely to engage a quit attempt when they receive even minimal intervention (< 3 minutes),
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and those lasting 30-90 minutes have been shown to increase abstinence rates nearly three-fold
(Fiore et al., 2008).
The tailored intervention included a novel psychoeducation component that was informed
by several theories of health behavior change and empirical evidence that providing smokers
with an explicit link between continued smoking and illness increases motivation to quit
(McCaul et al., 2006). First, the Transtheoretical Model (TTM) represents an integrative,
biopsychosocial approach to conceptualizing health behavior change that has been applied
extensively to the study of tobacco cessation (Prochaska & DiClemente, 1983; Prochaska,
Redding, & Evers, 2008). Core components of the TTM include stages of change, which
classifies readiness to quit smoking according to smokers’ stated intention and measurable steps
toward quitting, and decisional balance between the perceived positive and negative effects of
smoking. The TTM predicts that smokers may be motivated to progress from one stage to the
next as they come to perceive discrepancy between positive and negative effects of smoking.
Thus, smokers in pain may become more motivated to quit once they perceive a discrepancy
between continued smoking and their desired pain outcomes.
Second, the Health Belief Model (HBM) posits that individuals are more likely to change
an unhealthy behavior if they believe that (a) they are susceptible to negative health outcomes,
(b) the negative health outcomes will be severe in nature, and (c) behavior change will be
effective in alleviating or reducing these negative outcomes (Champion & Skinner, 2008). Pain
has been conceptualized as an aversive state that demands attention and orients behavior towards
escape/alleviation (Eccleston & Crombez, 1999), and smokers in pain likely hold a salient desire
for reduced pain and improved functioning. Therefore, a novel psychoeducation component that
addresses pain-smoking interrelations may increase motivation to quit because: (a) smokers may
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perceive themselves as immediately susceptible to the negative pain-related effects of smoking,
(b) pain is likely to be perceived as a severe health outcome, and (c) smokers may come to
understand the pain-related benefits of quitting.
A related concept, the “teachable moment,” describes a context or event in which
behavior change may become more salient due to health concerns, and tobacco use is thought to
provide a prototypical teachable moment due its broad range of deleterious health effects
(Lawson & Flocke, 2009). It is our contention that addressing smoking in the context of pain
may provide an optimal “teachable moment,” as smokers in pain may become more motivated to
quit if they come to understand the extent to which continued smoking may increase or maintain
their pain.
Intervention Conditions
Active condition (i.e., tailored intervention). Participants randomized to the active
condition received an intervention that was tailored to address smoking in the context of pain.
Consistent with existing evidence-based treatments (e.g., Perkins et al., 2008), the tailored
intervention included personalized feedback and assisted participants in developing discrepancy
between continued smoking and their health-related goals. The feedback and discrepancy
components were tailored to address smoking in the context of pain by focusing on pain-smoking
interrelations (i.e., personalized feedback address both pain and smoking; discrepancy targeted
pain-related goals). The third component of the active intervention was anovel pain-smoking
psychoeducation component, which included information about the deleterious effects of
smoking on pain and the potential pain-related benefits of smoking cessation. In accordance with
recommendations for evidence-based brief smoking interventions and motivational
enhancement, the intervention was delivered in a collaborative, warm, and empathic tone
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(Emmons, 2007; SAMHSA, 2012). For example, the psychoeducation component was delivered
using the “elicit – provide – elicit” framework, in which study therapists (1) elicited permission
to discuss pain/smoking, (2) provided educational information, and (3) elicited feedback from the
participant about the information that was provided. The therapist guide for the active
intervention is included in Appendix B and the educational handout is included in Appendix C.
Control condition (i.e., control intervention). Participants randomized to the control
condition received a 3As (ask, advise, arrange) intervention, which is an effective smoking
treatment recommended by Clinical Practice Guidelines (Fiore et al., 2008). Specifically,
participants were (1) asked about their smoking status and motivation to quit, (2) advised to quit
smoking, and (3) offered resources to help them quit, including self-help materials (i.e., Clearing
the Air; National Cancer Institute) that have been widely utilized as a behavioral smoking
intervention in randomized clinical trials (Lancaster, Stead, Silagy, & Sowden, 2000). The 3As
intervention is widely used as a standard of care in medical practices, and has demonstrated
effectiveness for increasing smoking abstinence rates (Fiore et al., 2008). We selected the 3As
intervention as a control because it allowed us to test whether the tailored intervention improves
outcomes relative to current practice (Arean & Alvidrez, 2002; Mohr et al., 2009). The therapist
guide for the control intervention is included in Appendix D.
Outcome Measures
Motivation to quit smoking. Cessation motivation is a multidimensional construct
(Nezami, Sussman, & Pentz, 2003) that is comprised of both cognitions about quitting (e.g., I
have a desire to quit smoking) and measurable steps towards behavior change (e.g., seeking
treatment). Motivation to quit was assessed with three self-report measures that target specific
and distinct facets of the motivation construct.
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Thoughts about abstinence. The Thoughts About Abstinence Scale (TAA; Hall,
Havassy, & Wasserman, 1990) is a reliable and valid measure that uses three separate Numerical
Rating Scales (NRS) to assess desire to quit smoking (0 = no desire to quit, 10 = full desire to
quit), anticipated success in quitting (0 = lowest expectation of success, 10 = highest expectation
of success), and anticipated difficulty quitting (0 = lowest amount of difficulty, 10 = highest
amount of difficulty). The TAA has previously been used to assess motivation to quit and
expectations for smoking cessation among smokers in pain (Ditre, Kosiba, Zale, Zvolensky, &
Maisto, 2016).
Contemplation ladder. The contemplation ladder (Biener & Abrams, 1991) is a widely
used, reliable, and valid measure of motivation to quit smoking on an 11-point Visual Analogue
Scale (VAS). The contemplation ladder includes anchor points at 0 (no thought of quitting), 2 (I
think I need to consider quitting someday), 5 (I think I should quit but not quite ready), 8
(starting to think about how to change my smoking patterns), and 10 (taking action to quit, e.g.,
cutting down, enrolling in a program). The contemplation ladder has previously been used to
assess motivation to quit among smokers in pain (Zale et al., 2014).
Motivation rulers. Motivation rulers for smoking cessation (Boudreaux et al., 2012)
consist of three separate NRSs that assess importance of quitting (0 = not important at all, 10 =
most important goal of my life), readiness to quit smoking in the next month (0 = not ready at all,
10 = 100% ready), and confidence that “you will quit smoking” in the next month (0 = not at all
confident, 10 = 100% confident). Motivation rulers have previously demonstrated reliability and
validity for assessing smoking motivation among medical populations (Boudreaux et al., 2012).
Knowledge of pain-smoking interrelations. The Pain and Smoking Questionnaire
(PSQ) is a 25-item questionnaire developed by members of our research team to assess
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knowledge of interrelations between pain and tobacco smoking. A total of 17 items assess
knowledge of associations between smoking and multiple health conditions (e.g., lung cancer,
heart disease, diabetes). Eight separate items assess specific knowledge of pain-smoking
interrelations, including whether smoking can cause chronic pain, contribute to pain-related
impairment in functioning, reduce the effectiveness of prescription pain medications, provide
acute analgesic effects, or help to distract from pain. Pain-specific items also assess knowledge
of whether pain can motivate smoking behavior or whether quitting smoking is associated with
improved pain and physical functioning. Response options for each item are yes, no, or not
sure/don’t know. The PSQ was scored as the number of total pain-smoking items that were
correctly answered (range 0 – 8), with higher scores representing a greater number of correct
responses.
Cessation treatment engagement. Motivation to engage cessation treatment was
assessed pre- and post-intervention as (1) willingness to learn about treatment options, (2)
interest in engaging treatment, and (3) intention to engage treatment in the next 30 days.
Willingness to engage treatment was assessed with the question “would you like to learn about
options for treatment to help you quit smoking?” Participants who answered yes were then given
a list of treatment options (i.e., medication/primary care, Quitline, behavioral health, or none of
the above), and asked whether they were interested in using any of the treatments and whether
they planned to enroll in any of the treatments in the next 30 days. Multiple responses were
permitted. For each question, participants who selected at least one treatment option were
considered to have indicated interest in treatment and an intention to enroll in treatment,
respectively. At one-month follow-up, engagement in treatment over the past 30 days was
assessed (yes/no) for each treatment option.
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Treatment satisfaction. The Client Satisfaction Questionnaire (Larsen, Attkisson,
Hargreaves, & Nguyen, 1979) was used to assess satisfaction with the study interventions. The
CSQ includes individual items that measure perceived quality of the treatment (0 = poor, 3 =
excellent), satisfaction with the treatment (0 = very dissatisfied, 3 = very satisfied), and whether
participants felt the treatment was helpful, would seek treatment again or recommend treatment
to a friend (0 = no, definitely not, 3 = yes, definitely).
Perceived discrepancy between smoking and desired pain outcomes. An open-ended
text box was included for participants to provide comments about reasons why the tailored
intervention did or did not improve their motivation to quit smoking. Perceived discrepancy
between smoking and desired pain outcomes was coded as yes/no. Comments were coded as
indicative of discrepancy only if participants made statements specifically about “pain” or
“chronic pain.” All other statements, including associations between smoking and general health,
were coded as not indicative of perceived discrepancy.
Demographics, Smoking, and Pain History
Demographics. The demographics form assessed age, gender, marital status,
race/ethnicity, education, and household income. This demographics form has been previously
used to asses sociodemographic characteristics among smokers in pain (Ditre et al., 2015; Ditre,
Zale, Kosiba, & Zvolensky, 2013; Zale et al., 2014).
Smoking history. The Smoking History Form (Brown, Lejuez, Kahler, & Strong, 2002)
is a widely used assessment of smoking behavior, including smoking rate, age of smoking
onset/years of smoking, and prior attempts to quit smoking. The Smoking History Form has been
used previously as a descriptive measure of smoking characteristics among smokers in pain
(Ditre et al., 2013; Zale et al., 2014).
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Exhaled carbon monoxide (CO). Exhaled CO was assessed using the CoVita
Smokerlyzer Micro+TM (Bedfont Scientific; Haddonfield, NJ). Exhaled CO is a well-established
and non-invasive objective measure of tobacco smoking (Benowitz et al., 2002; Evans, Sutton,
Oliver, & Drobes, 2015; Piper & Curtin, 2006), which is highly correlated with smoking
heaviness and time since last cigarette (Hung, Lin, Wang, & Chan, 2006; Kwok, Taggar, Cooper,
Lewis, & Coleman, 2014). A cut-off of 4 ppm has been identified as a reliable indicator of
cigarette use in the previous 24 hours (Cropsey, Eldridge, Weaver, Villalobos, & Stitzer, 2006;
Javors, Hatch, & Lamb, 2005; Raiff, Faix, Turturici, & Dallery, 2010).
Smoking dependence. The Heaviness of Smoking Index (HSI; Heatherton, Kozlowski,
Frecker, Rickert, & Robinson, 1989) is a two-item measure that assesses time to first cigarette
after waking and number of cigarettes smoked per day. Responses options are assigned
numerical values between 0 and 3, and items are summed to generate a total score (range 0-6),
with higher scores representing greater levels of smoking dependence. The HSI has been shown
to reliably predict cessation outcomes (Borland, Yong, O'Connor, Hyland, & Thompson, 2010;
Fagerstrom, 2012), and has been previously used among smokers in pain (Ditre, Kosiba, et al.,
2016).
Stages of change. The Stages of Change (SOC; DiClemente et al., 1991) is a three item
measure that is widely-used to classify motivation to quit smoking according to the
Transtheoretical Model of Behavior Change (Prochaska & DiClemente, 1983; Prochaska et al.,
2008). The SOC algorithm includes three items, which assess whether participants are seriously
considering quitting smoking in the next 6 months or the next 30 days and the number of pastyear quit attempts that lasted greater than 24 hours. Participants are classified as in either
precontemplation (no consideration of quitting), contemplation (consideration of quitting but no
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past-year quit attempt), or preparation (consideration of quitting in the next 30 days and one or
more past-year quit attempts). The SOC has previously been used to classify stages of change
among smokers with chronic pain (Zale et al., 2014).
Chronic pain grade. The Graded Chronic Pain Scale (GCPS; Von Korff, 2011) is a
reliable and valid measure of chronic pain severity, which was designed for use both in the
general population and among treatment-seeking pain patients. The GCPS includes 3 separate
NRSs (0 = no pain, 10 = pain as bad as could be) that assess pain right now, worst pain in the
past 3 months, and average pain in the past 3 months, and three 3 separate NRSs (0 = no
interference, 10 = unable to carry on any activities) that assess pain-related interference with
daily activities, recreation/social/family activities, and ability to work over the past 3 months. An
additional item assesses pain-related days of interference in the past 3 months. The GCPS yields
a characteristic pain intensity score (range 0 – 30), an interference score (range 0 – 40), and a
classification of chronic pain grade that accounts for both pain intensity and interference (Grade I
= low intensity/low interference; Grade II = high intensity/low interference; Grade III = high
disability/moderate interference; Grade IV = severe interference). The GCPS has previously been
used to assess chronic pain status among smokers in pain (Ditre, Kosiba, et al., 2016; Ditre et al.,
2013), and demonstrated good internal consistency in the current sample (α = .898).
Pain history. Descriptive information regarding pain history (e.g., pain duration and
frequency) and pain treatment (e.g., satisfaction with treatment from doctors and pain
specialists/pain treatment programs) was assessed using items adapted from the Kansas
Behavioral Risk Factor Surveillance System (Toblin, Mack, Perveen, & Paulozzi, 2011).
Participants also indicated the primary source of their pain (e.g., back pain, arthritis/rheumatism,
migraines) and responded (yes/no) to an item adapted from the National Comorbidity Survey-
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Replication (Kessler et al., 2004), which asked “do you currently have medically unexplained
chronic pain? This is defined as pain lasting six months or longer that is severe enough to either
interfere a lot with your normal activities or to cause a lot of emotional distress and that a doctor
cannot find a physical cause to explain.”
Potential Covariates
Pain and smoking expectancies. The Pain and Smoking Inventory (PSI; Ditre, Zale,
Heckman, & Hendricks, 2016) is a 9-item measure of perceived interrelations between pain and
tobacco smoking. Items assess the extent to which participants perceive their own pain and
smoking to be related across three domains (pain as a motivator of smoking, smoking to cope
with pain, and pain as a barrier to smoking cessation) using a 7-point Likert scale (0 = not at all
true, 3 = somewhat true, 6 = extremely true). The total score for the PSI is the average of all 9items, with higher scores representing greater perceived relations between pain and smoking
behavior. The PSI has previously been shown to distinguish between smokers with and without
chronic pain (Ditre, Zale, et al., 2016), and demonstrated excellent internal consistency in the
current sample (α = .910).
Pain-related anxiety. Pain-related anxiety was assessed using the Pain Anxiety
Symptoms Scale (PASS-20; McCracken & Dhingra, 2002), which measures the frequency of 20
prototypical anxious or fearful responses to pain (e.g., I worry when I am in pain; I try to avoid
activities that cause pain) using a 7-point Likert Scale (0 = never, 6 = always). Greater total
scores (range 0 – 120) represent greater levels of pain-related anxiety. The PASS-20 has been
previously used to investigate relations between pain and tobacco smoking among smokers in
pain (Ditre et al., 2015; Ditre et al., 2013; LaRowe et al., under review), and demonstrated
excellent internal consistency in the current sample (α = .922).
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Prescription opioid misuse. The Prescription Opioid Misuse Index (POMI; Knisely,
Wunsch, Cropsey, & Campbell, 2008) assesses six prototypical signs of opioid misuse (e.g.,
taking more medication than prescribed, feeling high or buzzed after using mediation).
Responses (0 = no, yes = 1) are summed to generate a total score, with high scores representing
greater levels of misuse. Consistent with scoring recommendations, a cut-off score of 2 was also
used to categorize misuse behavior (yes/no). The POMI demonstrated adequate internal
consistency in the current sample (α = .803).
Depression and anxiety symptoms. The Patient Health-Questionnaire-4 (PHQ-4;
Kroenke, Spitzer, Williams, & Lowe, 2009) is a reliable and valid screening tool for anxiety and
depression that was designed for use in medical populations. The PHQ-4 consists of two items
that assess frequency of depression symptoms (i.e., feeling down, depressed or hopeless; little
interest or pleasure in doing things) and two items that assess frequency of anxiety symptoms
(i.e., feeling anxious, nervous, or on edge; not able to stop or control worrying) during the past
two weeks. Response scales range from 0 (not at all) to 3 (nearly every day). Items are summed
to generate separate scores for depression and anxiety symptoms, with higher scores indicating
higher symptom severity. Consistent with scoring recommendations, a cut-off score of 3 was
used to distinguish potential presence of major depression or generalized anxiety, respectively.
The depression and anxiety symptom scales each demonstrated adequate internal consistency in
the current sample (α = 782 and α = .826, respectively).
Alcohol use. The Alcohol Use Disorders Identification Test-C (AUDIT-C; Bush,
Kivlahan, McDonell, Fihn, & Bradley, 1998) is a three item self-report measure of alcohol use
during the past year. Items assess frequency of alcohol consumption, typical amounts of alcohol
consumed per drinking episode, and frequency of binge (i.e., ≥ 6 drinks in one drinking episode)
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drinking. The AUDIT-C yields a continuous total score (range 0 – 12), with greater scores
representing greater levels of alcohol use. Cut-off scores of 4 for men and 3 for women can be
used to distinguish hazardous drinking. The AUDIT-C demonstrated adequate internal
consistency in the current sample (α = .865).
Procedure
All procedures were approved by the Institutional Review Board of Syracuse University.
In person appointments were conducted in the Pain and Addictions Research Lab, which is
housed within an outpatient medical building. Upon arrival to the in-person session, participants
provided written informed consent and exhaled CO. Participants then were left alone to complete
a battery of computerized self-report questionnaires that assessed baseline levels on all outcome
variables, sociodemographic, smoking and pain characteristics, and potential covariates.
Following baseline measures, participants were randomized to either the tailored or control
intervention, and the intervention was delivered face-to-face by a trained study therapist.
Participants were then left alone to complete the battery of computerized post-intervention
outcome measures. At the end of the in-person session, participants were provided with a
reminder card for the one-month telephone follow-up and $25 compensation for their time and
travel. Participants were contacted via telephone at one-month follow-up, and outcome measures
were administered verbally by trained research assistants. Research assistants were not informed
of the participant’s condition assignment prior to conducting the telephone follow-up. Figure 1
presents a study timeline, and Figure 2 presents the complete flow of participants through the
study.
Therapist Training and Treatment Fidelity
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The study interventions were delivered by the lead author (ELZ) and another clinical
psychology doctoral student (MJD). The majority (82.9%) of interventions were conducted by
the lead author (ELZ). Chi square analysis revealed no differences (p = .07) in the proportion of
active and control interventions completed by each therapist. Study therapists were trained on all
protocols by the lead author (ELZ) and the clinical supervisor, who is a licensed Clinical
Psychologist (JWD). Prior to beginning the study, both study therapists completed multiple role
plays of the tailored and control interventions. For each participant, study therapists completed
an intervention checklist during the visit to ensure adherence to the tailored and control
interventions (see Appendix E and Appendix F, respectively). All intervention sessions were
audio-recorded, and the study therapists also met regularly to review intervention tapes and
monitor fidelity.
Data Analytic Plan
All analyses were completed using SPSS Version 22 (IBM; 2013). First, group
differences in baseline variables (e.g., demographics, smoking characteristics, pain
characteristics) were examined using t-tests and chi-square analyses in order to verify that
randomization was successful. No differences were observed on any baseline variables (all ps >
.082).
Post-intervention outcomes were analyzed with an intent-to-treat approach. Analysis of
covariance (ANCOVA) and logistic regression were used to test main effects of the intervention
condition on knowledge of pain-smoking interrelations, motivation to engage a serious quit
attempt, and intention to engage smoking cessation treatment. Separate ANCOVAs (controlling
for respective baseline scores) were conducted with intervention condition entered as the fixed
factor and each continuous outcome (e.g., contemplation ladder) entered as the respective

19
dependent variables. Separate logistic regression models (controlling for respective baseline
scores) were utilized to test the effects of intervention condition and all dichotomous outcome
variables (e.g., intention to engage smoking cessation treatment). We then tested increased
knowledge of pain-smoking interrelations as a mediator of observed effects of treatment
condition on post-intervention motivation to quit and engage smoking cessation treatment.
Separate mediation models were tested for each outcome using the PROCESS Macro for SPSS
(Hayes, 2013), which employs a bootstrapping approach, can accommodate both dichotomous
and continuous variables, and yields estimates of direct and indirect effects of all predictor and
mediator variables (Preacher & Hayes, 2008). We also conducted ANCOVA and logistic
regression analyses (controlling for respective baseline scores) among participants who received
the tailored intervention to test associations between perceived discrepancy (entered as the fixed
factor) and each outcome variable.
One-month follow-up outcomes were analyzed for all participants who provided data (N
= 59)1 using a modified intent-to-treat approach (Gupta, 2011). For continuous variables,
repeated measures analysis of variance (ANOVA) was used with intervention condition entered
as the fixed factor, and all three assessment time points (baseline, post-intervention, 1-month
follow-up) entered as dependent variables. Separate logistic regression models were used to test
the effects of the intervention on dichotomous behavioral smoking variables (i.e., self-reported
quit attempt, self-reported use of available treatment resources).
Results
Participant Characteristics
Participants included 76 daily tobacco smokers (57.9% female; 42.1% Black or African
American; Mage = 42.71, SD = 13.42), who reported smoking approximately 18 cigarettes per day
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(SD = 10.71) for an average of 26 years (SD = 12.76). The average HSI score was 3.37 (SD =
1.21), indicating a moderate level of tobacco dependence (e.g., Chaiton, Cohen, McDonald, &
Bondy, 2007). The majority (59.2%) of participants endorsed having made a serious attempt to
quit smoking in the past, and 42% of those with a past quit attempt reported that they had never
received treatment for smoking cessation. With regard to SOC, more than one third of
participants were classified as precontemplation (35.5%) and one half of participants (51.3%)
were classified as contemplation.
The majority of participants reported experiencing chronic pain for at least one year
(78.9%), and that they were experiencing pain at more than one location in the body (64.5%).
The most commonly endorsed sources of chronic pain were chronic low back pain (55.3%),
chronic back pain (46.1%), arthritis/rheumatism (32.9%), and chronic neck pain (31.6%). Mean
ratings of pain on average over the past 3 months (M = 6.76, SD = 2.08) indicate that the sample
was experiencing moderate pain that was clinically significant (Krebs, Carey, & Weinberger,
2007). More than one third of participants reported daily use of pain medications (37.3%), and
29% reported current use of prescription opioids or narcotic pain medications.
Sociodemographic, smoking, and pain characteristics are presented in Table 1.
Post-Intervention Outcomes
Knowledge of pain-smoking interrelations. As hypothesized, results of ANCOVA
indicated that the tailored intervention increased knowledge of pain-smoking interrelations (see
Figure 3). Of the eight questions on pain-smoking interrelations, participants randomized to the
tailored intervention correctly answered three more questions than did participants in the control
condition, F(1,73) = 82.37, p < .001, ɳ2p = .53. Participant responses at each time point are
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presented in Table 2. Unadjusted means and standard deviations for knowledge scores are
presented in Table 3, and adjusted means and standard errors are presented in Table 4.
Motivation to quit smoking. As hypothesized, ANCOVA revealed that the tailored
intervention increased multiple indices of cessation motivation (see Table 4). Specifically,
participants randomized to the tailored intervention scored higher on the contemplation ladder,
F(1,73) = 11.54, p = .001, ɳ2p = .14, and reported greater desire to quit smoking, F(1,73) = 7.40,
p = .008, ɳ2p = .09. The tailored intervention also increased expected success in quitting, F(1,73)
= 12.95, p = .001, ɳ2p = .15. A trend-level association was observed for greater confidence in
quitting among participants who received the tailored intervention F(1,73) = 3.68, p = .059, ɳ2p =
.05. No group differences were observed with regard to self-reported importance (p = .237),
readiness (p = .138), or anticipated difficulty quitting (p = .703). Intercorrelations between
baseline measures of motivation to quit smoking are presented in Table 5.
Motivation to engage cessation treatment. As hypothesized, results of logistic
regression revealed that the tailored intervention increased willingness to learn about cessation
treatments (Wald χ2 = 5.91, p = .015). Participants randomized to the tailored intervention were
also more likely to indicate that they would be interested in using cessation treatment in the
future (Wald χ2 = 7.70, p = .006), and that they intended to engage treatment in the next 30 days
(Wald χ2 = 9.06, p = .003). Follow-up analyses revealed that the tailored intervention increased
interest and intention to engage the Quitline and talk to their doctor/mediation (see Table 6).
Knowledge of pain-smoking interrelations as a mediator of post-intervention
outcomes. As depicted in Figure 4, we observed an indirect effect of the tailored intervention on
greater desire to quit (b = .84, SE = .45, 95% CI [0.03, 1.81]) and willingness to learn about
cessation treatments (b = 2.66, SE = 1.46, 95% CI [0.13, 4.90]) via increased knowledge of pain-
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smoking interrelations. Increased knowledge of pain-smoking relations did not mediate treatment
effects on contemplation ladder scores (b = .31, SE = .60, 95% CI [-0.92, 1.44], expected success
in quitting (b = .15, SE = .52, 95% CI [-0.97, 1.12]), or intention to engage cessation treatment (b
= .86, SE = .72, 95% CI [-0.52, 2.36]).
Perceived discrepancy between continued smoking and desired pain outcomes. The
majority (n = 32) of participants in the active intervention provided comments about why the
intervention did or did not increase motivation to quit smoking (see Table 7). All participants
who provided feedback that indicated discrepancy (n = 13) between continued smoking and
desired pain outcomes also reported that the intervention helped to increase their motivation to
quit smoking. However, no differences were observed on any outcome variables between
participants who did and did not report discrepancy (all ps > .149).
One-Month Follow-Up Outcomes
Participant characteristics. A total of 59 (78%) participants provided data at one-month
follow-up. There was no association between intervention condition assignment and loss to
follow-up (χ2 = 1.89, p = .169), indicating that attrition did not differ between groups. The
primary reasons for loss to follow-up were disconnected/out of service telephone number
(58.8%) and did not return multiple voicemail messages (29.4%). Examination of baseline
variables revealed that participants who provided follow-up data were older (M = 44.64, SD =
12.98) than participants who did not provide follow up data (M = 36.29, SD = 13.27), t(74) =
2.32, p = .023. Participants who provided follow-up data also reported smoking fewer cigarettes
per day at baseline (M = 15.98, SD = 9.17), relative to those who did not provide follow-up data
(M = 23.41, SD = 12.70), t(74) = 2.61, p = .011.
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Smoking behavior and engagement of smoking cessation treatment. Results of
logistic regression revealed that participants who received the tailored intervention were more
likely to report having subsequently talked to their doctor about smoking (OR = 4.12, 95% CI
[1.12, 15.21], Wald χ2 = 4.51, p =.034), relative to participants who received the control
intervention. Although four participants who received the tailored intervention reported having
quit smoking (vs. zero in the control condition), results of logistic regression indicated that
smoking status did not significantly differ between the two groups (p = .691). On average,
participants in both conditions reported smoking a similar number of cigarettes per day at followup (p = .387), and no differences were observed with regard to the number of participants who
reported cutting down on their smoking (p = ..739) or making a 24 hour quit attempt (p = .188).
Maintenance of treatment gains. Repeated measures ANOVA revealed that participants
who received the tailored intervention continued to report greater knowledge of pain-smoking
interrelations at one-month follow-up (M = 6.00, SE = .42), relative to participants who received
the control intervention (M = 4.43, SE = .40), F(1, 49) = 7.46, p = .009, ɳ2p = .13. No group
differences were observed in contemplation ladder scores (p = .18), reported desire to quit (p =
.83) or expected success in quitting (p = .16).
Intervention Satisfaction
Participants who received the tailored intervention reported a greater mean level of
satisfaction, relative to participants who received the control intervention, t(74) = 3.15, p = .002.
Participants in the tailored intervention also reported that they would be more likely to seek the
intervention again in the future, t(74) = 2.09, p = .040, and to recommend the intervention to a
friend, t(74) = 3.44, p = .001. The majority of participants who received the tailored intervention
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rated the handout as extremely helpful (60.5%) and easy to understand (76.3%). Complete
satisfaction ratings for the tailored and control interventions are presented in Table 8.
Discussion
Pain and tobacco smoking are highly comorbid critical national health problems, and
smokers may constitute a recalcitrant subgroup who face unique cessation challenges and could
benefit from tailored interventions (e.g., Borrelli, 2010; Ditre et al., 2011; Zale et al., 2014; Zale
et al., 2016). This is the first randomized controlled trial of a motivational intervention that has
been tailored to address smoking in the context of pain. Informed by existing evidence-based
interventions and empirical and theoretical conceptualizations of health behavior change, the
tailored intervention included a novel psychoeducation component that was designed to increase
knowledge of pain-smoking interrelations and assist smokers in developing discrepancy between
continued smoking and desired pain outcomes. When compared to a 3As intervention that is
recommended by Clinical Practice Guidelines and used in many medical settings as the standard
of care (Fiore et al., 2008), the tailored intervention increased knowledge of pain-smoking
interrelations, motivation to quit smoking, willingness to learn about smoking cessation
treatment, and intention to engage cessation treatment. At one-month follow up, treatment gains
in knowledge of pain-smoking interrelations were maintained, and participants who received the
tailored intervention were more likely to report having subsequently talked to their doctor about
smoking.
The tailored intervention included a novel psychoeducation component that provided
participants with clear and explicit links between smoking behavior and pain-relevant
processes/outcomes. At baseline, participants answered an average of 3/8 questions about painsmoking interrelations correctly, and the majority were unaware that smoking can cause chronic
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pain (59.2%), contribute to greater pain intensity (56.5%), or reduce the effectiveness of
prescription pain medications (75%). Participants who received the active intervention
demonstrated significant increases in knowledge of pain-smoking interrelations, correctly
answering 6/8 questions at post-intervention and one-month follow-up. Thus, results suggest that
smokers are responsive to psychoeducation about complex associations between pain and
tobacco, and that smokers with chronic pain are able to learn and retain new information about
how smoking and pain are interrelated.
The tailored intervention (vs. 3As control) increased multiple self-report and behavioral
indices of motivation to quit smoking at post-intervention. Specifically, the tailored intervention
increased desire to quit smoking, contemplation ladder scores, and expected success in quitting.
Participants who received the tailored intervention were also more likely to demonstrate
willingness to learn about cessation treatments, interest in cessation treatment, and intention to
engage treatment in the next month. Increased knowledge of pain-smoking interrelations
mediated observed effects of the tailored intervention on increased desire to quit smoking and
willingness to learn about treatment options. Taken together, these findings are consistent with
evidence that providing smokers with clear and explicit links between smoking and health can
increase motivation to quit smoking (McCaul et al., 2006), and that smokers who are not yet
ready to quit may be amenable to interventions designed to increase motivation to quit and
engage abstinence-oriented treatment (Drake & Mueser, 2000).
At one-month follow-up, participants who received the tailored intervention were more
likely to report having subsequently engaged cessation treatment. Indeed, 37% of participants
who received the tailed intervention reported talking to their doctor about smoking (vs. 12.5% of
participants who received the 3A’s control). This finding could reflect greater initiative on the
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part of participants who received the tailored intervention to engage with their healthcare
provider. Given that Clinical Practice Guidelines recommend all smokers receive a brief
smoking intervention at every physician visit (Fiore et al., 2008), it is also possible that this
finding reflects greater receptivity towards interventions initiated by a healthcare provider. In
either case, these results provide initial evidence that the tailored pain-smoking intervention
increased willingness to engage future cessation treatment.
Results of the current study contribute to a growing multidisciplinary literature
examining pain-smoking interrelations, and suggest that smokers may become more motivated to
quit as they become aware of how continued tobacco smoking may interfere with their desired
pain outcomes. Results also indicate that a single, brief (i.e., 30 minute) session may be sufficient
to increase motivation to quit smoking and engage smoking cessation treatment among smokers
in pain. The tailored intervention was designed to be easily implemented in integrated health care
models (Funderburk et al., 2010; James & Folen, 2005), and it is possible that the intervention
could be employed in medical settings as a means of motivating smokers to quit and connecting
them to additional treatment (e.g., smoking cessation medications) in real time. Indeed, previous
work has demonstrated that smokers with chronic pain are amenable to pharmacologic smoking
interventions (Zale & Ditre, 2013), and talking to your doctor or using medication was the most
popular cessation treatment option selected by participants in the current study. Among
participants who received the tailored intervention, 76% were interested in talking to their
doctor/medication, 65% indicated that they intended to engage that treatment in the next 30 days,
and 37% reported having talked to their doctor about smoking at one-month follow-up. Thus,
these findings suggest that smokers with chronic pain may be receptive to tailored smoking
interventions that are designed to promote ongoing engagement with the healthcare system.
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Findings that the tailored pain-smoking intervention increased interest and willingness to
engage cessation resources are particularly relevant, given that the tailored intervention did not
increase self-reported readiness to quit. Evidence-based abstinence interventions assist patients
in preparing for a quit attempt by setting a quit date, removing smoking related triggers, and
developing strategies for coping with cravings and withdrawal symptoms (Cahill, Lancaster, &
Green, 2010; Perkins et al., 2008). Although participants who were willing to learn about
smoking cessation resources received a description of abstinence-oriented approaches (see
Appendix G), neither study intervention included a component specifically designed to support
smoking abstinence. Although results of the current study indicate that the tailored pain-smoking
intervention has the potential to increase multiple facets of motivation to quit smoking, and
additional abstinence-specific treatment components may be needed to increase readiness to
engage a serious quit attempt.
It is also notable that participants in the current study reported fairly low levels of formal
education, such that 40% of participants did not hold a high school diploma or GED. Although
the national prevalence of smoking has declined in the US, there remain significant disparities as
a function of educational achievement. In the general population, the prevalence of smoking
among persons who completed 9th-11th grade (31.6%) or received a GED (34.1%) is more than
double the national rate (15.1%), and when stratified by educational attainment, persons without
a high school diploma are the only group to have demonstrated an increase in smoking
prevalence over the past decade (Jamal et al., 2016). Thus, participants in the current study are
likely representative of a substantial portion of the smoking population. Persons with lower
levels of educational attainment are also more likely to demonstrate low levels of health literacy
(i.e., the ability process, understand, and use health information) and may have difficulty

28
communicating with healthcare providers (DHHS, 2008). Indeed, when treating patients with
low health literacy, providers tend to endorse low perceived effectiveness and may be reluctant
to offer health education to their patients (Seligman et al., 2005). Results of the current study are
encouraging because they suggest that low levels of educational attainment are not a barrier to
learning or retaining information about complex pain-smoking relations.
Clinical implications of this study include the possibility that health care providers may
use pain as a “teachable moment” to discuss smoking cessation with their patients. Consistent
with a phase-based framework for smoking cessation (Baker et al., 2011), healthcare providers
who deliver the tailored intervention should consider greater motivation towards smoking
cessation to be a successful treatment outcome. When possible, providers could capitalize on
increased motivation to quit and engage cessation treatment in real-time by immediately linking
patients to additional services. For example, healthcare providers can recommend cessation
medications, provide brief evidence-based behavioral interventions to support readiness to quit
(e.g., strategies for coping with cravings; Fiore et al., 2008) and proactively connect patients to
ongoing behavioral support via their state Quitline (i.e., via electronic Refer-to-Quit).
Results of the current study also have the potential to inform future research. First, a fully
powered clinical trial is needed to test the effectiveness of the tailored intervention in outpatient
medical settings. Such a trial could utilize medical record review to verify chronic pain status
and utilization of cessation treatments, as well as collect more detailed follow-up data over
multiple assessment points (e.g., number of doctor visits). An effectiveness trial that seeks to
evaluate delivery of the tailored intervention in a medical setting could also include a separate
component designed to educate providers about pain-smoking interrelations and train providers
to talk with their patients about pain and smoking. Second, future clinical trials should utilize a

29
control condition that includes a motivational intervention without the tailored pain-smoking
psychoeducation component (e.g., an intervention that provides general health education). Use of
an untailored control intervention that also targets similar motivational processes (e.g., increased
knowledge, perceived discrepancy) would allow for tests of the relative effects of pain-specific
content above-and-beyond effects of the general motivational components. Third, future research
should test whether booster sessions (e.g., in person or via telephone) help to maintain treatment
gains in motivation and desire to quit smoking. There is some evidence to suggest that shorter
visits at greater frequency contribute to improved cessation outcomes (Fiore et al., 2008), and
future research should test the optimal duration and frequency for delivery of the tailored
intervention. Fourth, future research should test the potential utility of further modifying the
tailored intervention, which was tailored to address smoking in the context of pain among
smokers not yet ready to quit, to match participant’s specific stage of change (e.g., precontemplation via contemplation) at baseline. Finally, future research should examine the utility
of delivering a similar intervention via methods that are more cost effective and do not require
effort from specialized providers, including internet and smart-phone based interventions
(Cunningham, 2007; Riper et al., 2009).
Strengths of the current study include assessment of multiple self-report and behavioral
indices of motivation to quit smoking, use of empirical and theoretical conceptualizations of
health behavior change to inform treatment development, and recruitment of a generalizable
sample of daily tobacco smokers. The current study also recruited participants who were not
seeking treatment for smoking cessation, which may increase generalizability to smokers who
could encounter the tailored intervention in the course of seeking other healthcare services (e.g.,
at a regularly scheduled primary care appointment). Despite these strengths, several limitations
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should be acknowledged. First, participants were recruited from the community, and we were
unable to verify their chronic pain status via medical record review. Second, although research
assistants conducted telephone follow-ups, study therapists conducted the in-person research
visits, which may have produced demand effects or desirability bias in participant responses.
However, we sought to limit these potential effects by leaving participants alone to complete
computerized assessments at pre- and post-intervention and assuring participants that all
responses were confidential. Third, we conducted a single follow-up assessment at one-month,
which may not have provided sufficient time for participants to engage medical services, and it is
not known whether participants in both conditions had equal opportunities to engage the
healthcare system during the follow-up period. Fourth, we tested the tailored intervention against
a 3As intervention that is recommended by Clinical Practice Guidelines and widely used in
medical practices (Fiore et al., 2008), which allows for conclusions about how the tailored
intervention performed relative to an intervention that participants are likely to receive in the
healthcare setting. However, it is not known whether the tailored intervention would serve to
increase motivation to quit and engage treatment above-and-beyond an untailored motivational
intervention that provides general health information (i.e., is not tailored to address pain-smoking
interrelations). Finally, although the 30-minute intervention is consistent with typical visit length
for integrated healthcare settings (Funderburk et al., 2010), it may be too long to deliver within a
standard medical appointment (Tai-Seale, McGuire, & Zhang, 2007). It is possible that the
tailored intervention may require additional adaptation (e.g., changes to visit length or
frequency) to achieve optimal feasibility and effectiveness in medical settings.
Taken together, results of the current study indicate that smokers with chronic pain may
become more motivated to quit smoking and engage cessation treatment as they become more

31
aware of how continued smoking may contribute to deleterious pain outcomes. These findings
contribute to an emerging literature on complex pain-smoking interrelations, and provide initial
support for the hypothesis that smokers with chronic pain may benefit from interventions that
have been tailored to address smoking in the context of pain. As such, the current results have
the potential to inform the treatment of smokers with chronic pain, including the ongoing
development of tailored interventions for this important subpopulation of smokers.
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Footnotes
1

Multiple imputation was considered as an alternative to restricting analyses to
participants who provided follow-up data. However, when multiple imputation was used, linear
mixed modeling revealed a similar pattern of results. Little’s MCAR test also indicated that data
were missing completely at random (p = .464). Given recommendations that pairwise or listwise
deletion can be used instead of imputation when data are MCAR (Garson, 2015), and evidence
from Monte Carlo Simulations that ANOVA performs similarly when samples are restricted to
complete data (Cheema, 2014), we elected to report results of analyses among participants who
provided follow-up data.
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Table 1
Sociodemographic, Smoking, and Pain Characteristics at Baseline
Intervention Condition
Tailored
Control
(n = 38)
(n = 38)
n (%)
n (%)
Gender
Male
Female
Race/Ethnicity
White
Black/African American
Other
Marital status
Single
Married
Widowed
Divorced/Separated
Education
Did not graduate high school
Graduated high school
Some college
Technical/Associates degree
Four years of college
Household income
<10,000
10,000-19,999
20,000-29,999
30,000-39,999
>40,000
Stages of Change
Precontemplation
Contemplation
Preparation
Previous Attempt to Quit
Yes
No
Chronic Pain Grade
I
II
III
IV
Duration of Chronic Pain
Less than 1 Year
1-3 Years
3-5 Years
5-10 Years

Total Sample
(N = 76)
n (%)

17 (44.7%)
21 (55.3%)

15 (39.5%)
23 (60.5%)

32 (42.1%)
44 (57.9%)

19 (50.0%)
15 (46.9%)
4 (10.5%)

21 (53.3%)
17 (53.1%)
0 (0.0%)

40 (52.6%)
32 (42.1%)
4 (5.3%)

18 (47.4%)
4 (10.5%)
2 (5.3%)
14 (36.8%)

25 (65.8%)
2 (5.2%)
2 (5.3%)
9 (23.7%)

43 (56.6%)
6 (7.9%)
4 (5.3%)
23 (30.2%)

16 (40.8%)
9 (23.7%)
8 (21.1%)
5 (13.2%)
0 (0.0%)

15 (39.5%)
10 (26.3%)
8 (21.1%)
4 (10.5%)
1 (2.6%)

31 (40.8%)
19 (25.0%)
16 (21.1%)
9 (11.8%)
1 (1.3%)

19 (50.0%)
11 (28.9%)
2 (5.3%)
2 (5.3%)
4 (10.5%)

21 (55.3%)
9 (23.7%)
4 (10.5%)
0 (0.0%)
4 (10.5%)

40 (52.6%)
20 (26.3%)
6 (7.9%)
2 (2.6%)
8 (10.5%)

15 (39.5%)
18 (47.4%)
5 (13.2%)

12 (31.6%)
21 (55.3%)
5 (13.2%)

27 (35.5%)
39 (51.3%)
10 (13.2%)

21 (59.2%)
17 (44.7%)

24 (63.2%)
14 (36.8%)

45 (59.2%)
31 (40.8%)

5 (13.2%)
6 (15.8%)
8 (21.1%)
19 (50.0%)

7 (18.4%)
6 (15.8%)
9 (23.7%)
16 (42.1%)

12 (15.8%)
12 (15.8%)
17 (22.4%)
35 (46.1%)

10 (26.3%)
11 (28.9%)
2 (5.3%)
6 (15.8%)

6 (15.8%)
6 (15.8%)
7 (18.4%)
6 (15.8%)

16 (21.1%)
17 (22.4%)
9 (11.8%)
12 (15.8%)
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More than 10 Years
Table 1. continued
Frequency of Pain Medication Use
Never/Rarely
1-3 Times/Month
1-2 Times/Week
Several Times/Week
Daily
Prescription Opioid Misuse
Yes
No
Willing to Learn about Cessation
Treatment Options
Yes
No
Interest in Using Cessation
Treatment
Yes
No
Intention to Engage Cessation
Treatment
Yes
No

9 (28.9%)

13 (34.2%)

22 (28.9%)

14 (36.8%)
0 (0.0%)
6 (16.2%)
5 (13.55)
12 (32.4%)

10 (27.0%)
2 (5.3%)
6 (15.8%)
4 (10.5%)
16 (42.1%)

24 (31.6%)
2 (2.7%)
12 (16.0%)
9 (12.0%)
28 (37.3%)

11 (28.96%)
27 (71.1%)

11 (28.96%)
27 (71.1%)

22 (28.9%)
54 (71.1%)

21 (55.3%)
17 (44.7%)

23 (60.5%)
15 (39.5%)

44 (57.9%)
32 (42.1%)

21 (55.3%)
17 (44.7%)

19 (50%)
19 (50%)

40 (52.6%)
36 (47.4%)

9 (23.7%)
29 (76.3%)

13 (34.2%)
25 (65.8%)

22 (28.9%)
54 (71.1%)

M (SD)
M (SD)
Age
42.76 (13.41)
42.79 (13.61)
Cigarettes per day
20.03 (13.24)
15.26 (6.76)
Heaviness of Smoking Index
3.58 (1.08)
3.16 (1.31)
Exhaled CO
14.39 (9.67)
17.03 (9.91)
Years daily smoking
26.16 (13.44)
25.41 (12.20)
Past-Year Quit Attempts
1.71 (4.01)
1.74 (2.05)
Characteristic Pain Intensity
20.66 (4.63)
20.01 (5.74)
Characteristic Disability
22.16 (10.61)
21.00 (10.90)
Pain Days in Past 6 Months
128.05 (64.68)
123.60 (67.14)
Pain-Related Anxiety
58.68 (23.72)
63.29 (25.60)
Pain-Smoking Expectancies
2.63 (1.51)
2.94 (1.60)
Alcohol Use
2.42 (3.05)
2.29 (3.25)
Depression Symptoms
2.63 (2.11)
2.55 (2.13)
Anxiety Symptoms
2.47 (1.91)
2.95 (2.13)
Note. No significant differences were observed between treatment conditions.

M (SD)
42.78 (13.42)
17.64 (10.71)
3.37 (1.21)
15.69 (9.81)
25.79 (12.76)
1.73 (3.16)
20.34 (5.19)
21.58 (10.70)
125.83 (65.52)
60.99 (24.62)
2.79 (1.55)
2.68 (3.14)
2.59 (2.12)
2.59 (2.01)
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Table 2
Participant Responses to Items used to Assess Knowledge of Pain-Smoking Interrelations at
Baseline, Post-Intervention, and One-Month Follow-Up

Baseline
Can smoking cause chronic pain?
Tailored
Control
Can smoking make pain worse over time?
Tailored
Control
Can smoking make it more difficult to function physically
despite pain?
Tailored
Control
Can smoking reduce the effectiveness of prescription pain
medications?
Tailored
Control
Can the experience of pain make people want to smoke or
cause them to smoke more?
Tailored
Control
Can smoking directly reduce pain in a way that is similar to
analgesic pain medications?
Tailored
Control
Can smoking help to distract from pain?
Tailored
Control
Can quitting smoking help to improve pain and physical
function?
Tailored
Control
Post-Intervention
Can smoking cause chronic pain?
Tailored
Control
Can smoking make pain worse over time?
Tailored
Control
Can smoking make it more difficult to function physically
despite pain?
Tailored
Control
Can smoking reduce the effectiveness of prescription pain
medications?
Tailored
Control

Yes
n (%)

No
n (%)

Not Sure/
Don’t Know
n (%)

15 (39.5%)
16 (42.1%)

1 (2.6%)
3 (7.9%)

22 (57.9%)
19 (50.0%)

17 (44.7%)
16 (42.1%)

1 (2.6%)
2 (5.3%)

20 (52.6%)
20 (52.6%)

24 (63.2%)
21 (55.3%)

1 (2.6%)
2 (5.3%)

13 (34.2%)
15 (39.5%)

10 (26.3%)
9 (23.7%)

2 (5.3%)
3 (7.9%)

26 (68.4%)
26 (68.4%)

27 (71.1%)
27 (71.1%)

4 (10.5%)
3 (7.9%)

7 (18.4%)
8 (21.1%)

3 (7.9%)
5 (13.2%)

19 (50.0%)
18 (47.4%)

16 (42.1%)
15 (39.5%)

22 (57.9%)
19 (50.0%)

10 (26.3%)
9 (23.7%)

6 (15.8%)
10 (26.3%)

21 (55.3%)
23 (60.5%)

2 (5.3%)
1 (2.6%)

15 (39.5%)
14 (36.8%)

37 (97.4%)
17 (44.7%)

0 (0.0%)
2 (5.3%)

1 (2.6%)
19 (50.0%)

38 (100.0%)
18 (47.4%

0 (0.0%)
1 (2.6%)

0 (0.0%)
19 (50.0%)

37 (97.4%)
19 (50.0%)

0 (0.0%)
6 (15.8%)

1 (2.6%)
13 (34.2%)

36 (94.7%)
12 (31.6%)

1 (2.6%)
5 (13.2%)

1 (2.6%)
21 (55.3%)
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Table 2. continued
Can the experience of pain make people want to smoke or
cause them to smoke more?
Tailored
Control
Can smoking directly reduce pain in a way that is similar to
analgesic pain medications?
Tailored
Control
Can smoking help to distract from pain?
Tailored
Control
Can quitting smoking help to improve pain and physical
function?
Tailored
Control

35 (92.1%)
26 (68.4%)

2 (5.3%)
3 (7.9%)

1 (2.6%)
9 (23.7%)

20 (52.6%)
7 (18.4%)

15 (39.9%)
15 (39.5%)

3 (7.9%)
15 (42.1%)

27 (71.1%)
24 (63.2%)

9 (23.7%)
7 (18.4%)

2 (5.3%)
7 (18.4%)

31 (81.6%)
19 (50.0%)

5 (13.2%)
5 (13.2%)

2 (5.3%)
14 (36.8%)

One-Month Follow-Up
Can smoking cause chronic pain?
Tailored
22 (88.0%)
1 (4.0%)
2 (8.0%)
Control
15 (53.6%)
2 (7.1%)
11 (39.3%)
Can smoking make pain worse over time?
Tailored
24 (96.0%)
0 (0.0%)
1 (4.0%)
Control
14 (50.0%)
1 (3.6%)
13 (46.4%)
Can smoking make it more difficult to function physically
despite pain?
Tailored
23 (90.0%)
0 (0.0%)
2 (8.0%)
Control
18 (64.3%)
5 (17.9%)
5 (17.9%)
Can smoking reduce the effectiveness of prescription pain
medications?
Tailored
17 (68.0%)
1 (4.0%)
7 (28.0%)
Control
11 (39.3%)
5 (17.9%)
12 (42.9%)
Can the experience of pain make people want to smoke or
cause them to smoke more?
Tailored
19 (76.0%)
2 (8.0%)
4 (16.0%)
Control
25 (89.3%)
1 (3.6%)
2 (7.1%)
Can smoking directly reduce pain in a way that is similar to
analgesic pain medications?
Tailored
8 (32.0%)
11 (44.0%)
6 (24.0%)
Control
5 (17.9%)
9 (32.1%)
14 (50.0%
Can smoking help to distract from pain?
Tailored
18 (72.0%)
3 (12.0%)
4 (16.0%)
Control
19 (67.9%)
5 (17.9%)
4 (14.3%)
Can quitting smoking help to improve pain and physical
function?
Tailored
19 (76.0%)
5 (20.0%)
1 (4.0%)
Control
17 (60.7%)
2 (7.1%)
9 (32.9%)
Note. Baseline and Post-Intervention N = 76; One-Month Follow-Up N = 59, 6 participants had missing data at OneMonth Follow-Up for some knowledge items.
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Table 3
Unadjusted Means and Standard Deviations of Continuous Outcome Variables
at All Time Points
Baseline
M (SD)

Post-Intervention
M (SD)

One-Month Follow-Up
M (SD)

Knowledge of Pain-Smoking
Relations
Tailored
3.66 (1.82)
6.87 (1.21)
Control
3.58 (2.07)
3.74 (2.26)
Contemplation Ladder
Tailored
5.08 (3.18)
6.87 (3.39)
Control
5.92 (2.87)
6.03 (2.95)
Desire to Quit
Tailored
5.29 (2.97)
6.87 (3.19)
Control
5.74 (2.67)
6.08 (3.08)
Expected Success in Quitting
Tailored
4.16 (2.51)
6.42 (2.99)
Control
4.32 (2.64)
4.89 (2.77)
Anticipated Difficulty Quitting
Tailored
7.45 (2.90)
6.42 (2.87)
Control
7.00 (2.48)
6.53 (2.67)
Readiness to Quit
Tailored
4.11 (3.54)
5.84 (3.97)
Control
4.97 (3.29)
5.50 (3.34)
Importance of Quitting
Tailored
6.55 (3.19)
7.24 (3.05)
Control
6.84 (2.80)
6.97 (2.93)
Confidence in Quitting
Tailored
3.11 (2.81)
4.55 (3.85)
Control
3.53 (3.12)
3.66 (2.98)
Note. Baseline and Post-Intervention N = 76. One-Month Follow-Up N = 59.

6.00 (1.96)
4.43 (2.20)
6.96 (2.63)
5.97 (2.87)
6.69 (2.68)
6.52 (3.22)
6.31 (2.88)
5.16 (3.12)
7.00 (2.86)
7.55 (2.34)
5.50 (4.12)
5.40 (3.95)
8.73 (1.76)
7.50 (2.60)
5.19 (4.06)
4.43 (2.20)
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Table 4
Adjusted Means and Standard Errors of Continuous Outcome Variables at Post-Intervention
Intervention Condition
Tailored
Control
M (SE)
M (SE)
Knowledge of Pain-Smoking Relations***
6.85 (0.24)
3.76 (0.24)
Contemplation Ladder**
7.19 (0.32)
5.67 (0.32)
Desire to Quit*
7.07 (0.31)
5.88 (0.31)
Expected Success in Quitting**
6.46 (0.33)
4.83 (0.33)
Anticipated Difficulty Quitting
6.36 (0.44)
6.59 (0.44)
Readiness to Quit
6.15 (0.45)
5.19 (0.45)
Importance of Quitting
7.35 (0.29)
6.86 (0.29)
†
Confidence in Quitting
4.70 (0.44)
3.51 (0.44)
Note. N = 76. Means and standard errors adjusted for baseline levels of each respective
variable.
*p < .01. **p = .001. ***p < .001. †p = .059.
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Table 5
Intercorrelations between Measures of Motivation to Quit Smoking at Baseline

1. Contemplation Ladder
2. Desire to Quit
3. Expected Success in
Quitting
4. Anticipated Difficulty
Quitting
5. Readiness to Quit
6. Importance of Quitting
7. Confidence in Quitting
Note. N= 76.
*p < .01. ***p < .001.

1.
--

2.
.69***
--

3.
.42***
.60***
--

4.
.23*
.23*
.01

5.
.76***
.76***
.42***

6.
.78***
.78***
.46***

7.
.55***
.55***
.44***

--

.08

.13

-.06

--

.66***
--

.67***
.48***
--
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Table 6
Post-Intervention Willingness to Learn About, Interest in, and Intention to Engage Available
Smoking Cessation Treatments
Intervention Condition
Tailored
Control
n (%)
n (%)

OR [95% CI]

Willing to learn about treatment
resources

36 (94.7%)

28 (77.8%)

7.74 [1.49, 40.30]*

Interested in using cessation
treatment
Talk to doctor/medication
Quitline
Behavioral Health

36 (94.7%)
32 (84.2%)
29 (76.3%)
9 (23.7%)

25 (65.8%)
21 (55.3%)
7 (18.4%)
1 (2.6%)

9.55 [1.94, 47.02]**
4.27 [1.37, 13.28]*
18.81 [5.35, 66.07]*
11.78 [1.40, 99.88]*

Intention to engage treatment
resources
30 (78.9%)
18 (47.4%)
5.15 [1.77, 14.96]**
Talk to doctor/medication
25 (65.8%)
14 (36.8%)
4.04 [1.47, 11.09]**
Quitline
22 (57.9%)
6 (15.8%)
9.80 [2.91, 33.02]***
Behavioral Health
3 (7.9%)
1 (2.6%)
2.91 [0.29, 29.43]
Note. N = 76. Odds Ratio (OR) adjusted for baseline levels of each respective variable.
*p < .05. **p < .01. ***p < .001.
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Table 7
Participant Comments about the Tailored Intervention
Perceived Discrepancy
Yes

No

Participant Comment
being able to not have this chronic pain anymore
decrease in pain
I dont want to be in pain for the rest of my life
making my pain feel better
my pain
pain
Smoking and how it can worsen my pain
that my smoking does have a impact on my pain
that smoke can also cause pain
the information on how smoking was making my pain worst
the link between my chronic pain and smoking

about the brain and having to depend on others
all aspects
Because I’m not ready
carbon monoxide level
everything was helpfu
health
help factors available
mabey
more info on smoking
no desire to quit
no it did not.I dont want to quit
suffice info
not ready
talking about all the negative impacts of smoking
telling me my carbon levels are high
the scale
trying to understand why i smoke
yes
very much
Note. Six participants did not provide a comment. All comments are exactly as typed by
participants; spelling and grammatical errors have not been corrected.
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Table 8
Participant Satisfaction with the Tailored and Control Interventions
Intervention Condition
Tailored
Control
M (SD)
M (SD)
2.63 (0.49)
2.21 (0.66)
2.71 (0.46)
2.24 (0.79)
2.55 (0.60)
2.21 (0.81)
2.55 (0.56)
2.11 (0.65)
2.45 (0.72)
1.76 (0.75)
2.71 (0.46)
2.24 (0.71)
2.55 (0.76)
2.16 (0.92)
2.45 (0.60)
1.95 (0.70)

Quality of Service**
Satisfaction with Service**
Would Seek Services Again**
Got Service You Wanted**
Service Met Your Needs***
Recommend Service to a Friend*
Satisfaction with Amount of Help Received*
Services Helped You Deal More Effectively
with Problems**
Note. All response scales 0-3, with higher scores representing greater satisfaction.
*p < .05. **p < .01. ***p < .001.
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Recruitment

Telephone
Screening

One-Month
Follow-Up

In-person Session
Computerized
Baseline
Measures and
Randomization
[15 minutes]

Figure 1. Study timeline.

Active
Control

Tailored
Intervention
[30 minutes]
Control Intervention
[10 minutes]

Computerized
Outcome
Measures
[15 minutes]

Telephone
Outcome
Measures
[15 minutes]
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Enrollment

Assessed for eligibility (n = 160)

Excluded (n = 84)
 Not meeting inclusion criteria (n = 66)
 Eligible but did not enroll (e.g.,
declined to participate; did not
attend first session; n = 18)

Enrolled and Randomized (n = 76)

Allocation
Allocated to tailored intervention (n = 38)
 Received allocated intervention (n = 38)

Allocated to control intervention (n = 38)
 Received allocated intervention (n = 38)

Follow-Up
Lost to follow-up (n = 11)

Lost to follow-up (n = 6)



Number not in service (n = 6)



Number not in service (n = 2)



Did not return multiple voicemails (n = 3)



Did not return multiple voicemails (n = 3)



Did not answer multiple calls/no voicemail (n = 1)



Did not answer multiple calls/no voicemail (n = 1)



Moved away (n = 1)

Analysis
Analysed
 Post-Intervention Outcomes (n = 38)
 One-Month Follow-Up Outcomes (n = 27)

Analysed
 Post-Intervention Outcomes (n = 38)
 One-Month Follow-Up Outcomes (n = 32)





Excluded due to loss to follow-up (n = 11)

Excluded due to loss to follow-up (n = 6)

Figure 2. Participant flow chart following CONSORT guidelines.
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8

**
***

*
**

7

6

5

4

Control
Tailored

3

2

1

0
Knowledge of PainSmoking Relations

Contemplation
Ladder

Desire to Quit

Expected
Success in Quitting

Figure 3. Post-intervention mean (adjusted) knowledge of pain-smoking interrelations and
motivation to quit as a function of intervention condition. Error bars represent standard error.
* p < .01. ** p = .001. *** p < .001.
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[M1] Knowledge of
Pain-Smoking
Interrelations

b path

a path

[Y1] Desire to Quit
[X1] Intervention
Condition

c path
c’ path

[Y2] Willingness to Accept
Information about Cessation
Treatment Options

[C1] Baseline Knowledge of PainSmoking Interrelations
[C2] Baseline Desire to Quit (for Y1)
[C2] Baseline Willingness to Accept
Information about Cessation Treatment
Options (for Y2)

Figure 4. Conceptual model of indirect associations between the tailored intervention and greater
post-intervention desire to quit and willingness to accept information about cessation treatment
via increased knowledge of pain-smoking interrelations. X = independent variable. M =
mediating variable. Y = Dependent Variable. C = Covariate.
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Appendix A
Measures
Screening Items
1. Do you now smoke cigarettes (read choices):
______ Not at all
______ Some Days
______ Every Day
2. Over the last week, how many cigarettes did you smoke per day on average? __________
3. Are you currently in treatment to help you quit smoking. By treatment I mean seeing a
counselor or therapist, using the quitline, or using a smoking cessation medication like
patches or gum. Check all that apply:
______ No
______ Yes, using medication, Clarify type of medication ____________________
______ Yes, seeing counselor or therapist
______ Yes, Quitline
4. How much bodily pain have you had during the past 4 weeks? (read choices)
______ None
______ Mild
______ Moderate
______ Severe
______ Very Severe
5. Do you currently suffer from any type of chronic pain, that is, pain that occurs constantly or
flares up frequently? Do not report aches or pains that are fleeting or minor
______ No
______ Yes
6. Using a 0 – 10 scale, where 0 is “no pain” and 10 is “pain as bad as could be”… During the
last 3 months, ON AVERAGE, how would you rate your pain?
Pain as bad
No Pain
as could be
0
1
2
3
4
5
6
7
8
9
10
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Thoughts About Abstinence Scale
First, I’d like to know how you feel about stopping smoking cigarettes at this time. On a scale
from 1 to 10, with 1 representing no desire to quit and 10 representing full desire to quit, give
yourself a rating. Chose the number between 1 and 10 that best describes your own desire to stop
smoking cigarettes at this time. Remember, the higher the number, the greater your desire.
 No Desire to Quit 1
 2
 3
 4
 5
 6
 7
 8
 9
 Full Desire to Quit 10
Now I’d like to know how successful you expect to be quitting smoking cigarettes at this time.
Be realistic about this, based on your past experiences and your present strength of motivation.
On a scale from 1 to 10, with 1 representing the lowest expectation of success and 10
representing the highest expectation of success, give yourself a rating of your own expectation of
success in quitting smoking cigarettes. Remember, the higher the number the greater the
expectation of success.
 Lowest Expectation of Success 1
 2
 3
 4
 5
 6
 7
 8
 9
 Highest Expectation of Success 10
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Now I’d like to know how difficult you think it will be for you to keep from smoking cigarettes
after having quit. On a scale from 1 to 10, with 1 representing the lowest amount of difficulty
and 10 representing the greatest amount of difficulty, give yourself a rating of how difficult you
think it will be for you to quit and remain abstinent. Remember, the higher the number, the more
difficult you think it will be for you to quit.
 Lowest Amount of Difficulty 1
 2
 3
 4
 5
 6
 7
 8
 9
 Highest Amount of Difficulty 10
Lastly, I want to know the GOAL you have chosen for yourself about smoking cigarettes at this
time. Please read the goals listed on this page and circle the one goal that best represents your
own goal at this time, and fill in blanks as indicated.
 I really don't have a clear goal in mind.
 I want to use cigarettes in a controlled manner – to be in control of how often I smoke and
how much I smoke. I would like to limit that to no more than _____ (amount) per _____
(time). ____________________
 I want to be totally abstinent from all cigarette use for a period of time, after which I will
make a new decision about whether or not I will smoke cigarettes again. For me, the time
period I want to be abstinent for is: ____________________
 I don’t want smoking cigarettes to be a habit for me anymore, but I would like to be able to
occasionally smoke cigarettes when I really have an urge.
 I want to quit smoking cigarettes once and for all, even though I realize I may slip up and
smoke cigarettes once and a while.
 I want to quit smoking cigarettes once and for all, be totally abstinent, and never smoke
cigarettes ever again for the rest of my life.
 None of the above applies exactly to me. My own goal is: ____________________
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Contemplation Ladder
Each rung on this ladder represents where various smokers are in their thinking about quitting.
Click on the number that indicates where you are now. Please select only one number.
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Motivation Rulers
How important is stopping smoking to you?
 Not Important at All 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Most important goal of my life 10
How ready are you to quit smoking within the next month?
 Not at All Ready 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 100% Ready 10
How confident are you that you will quit smoking within the next month?
 Not at All Confident 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 100% Confident 10
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Pain and Smoking Questionnaire
Below are a series of questions about relations between tobacco smoking and various health
conditions. We are interested in what you have already learned or know to be true (yes/no)
versus what you may not yet know or be sure about (not sure/don't know). In other words, these
questions are not asking about your opinions on these topics, but rather what you do or do not
know to be true according to scientific research findings.
Please indicate whether smoking has been associated with each of the following health
problems/conditions:
Yes

No

Not Sure/Don't Know

Lung Cancer
Chronic Obstructive
Pulmonary Disease
(COPD)













Heart Disease







Oral Disease







Pregnancy
Complications







Infertility
HIV










Chronic Pain







Diabetes







Please indicate whether smoking is a known risk factor for each of the following health
problems/conditions:
Yes

No

Not Sure/Don't Know

Lung Cancer







Heart Disease
Chronic Pain










Diabetes
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Has any health care provider ever talked to you about relationships between:
Yes

No

Not Sure/Don't Know

Smoking and lung
cancer
Smoking and heart
disease













Smoking and chronic
pain







Smoking and diabetes







Can smoking cause chronic pain?
 Yes
 No
 Not Sure/Don't Know
Can smoking make pain worse over time?
 Yes
 No
 Not Sure/Don't Know
Can smoking make it more difficulty to function physically despite pain?
 Yes
 No
 Not Sure/Don't Know
Can smoking reduce the effectiveness of prescription pain medications?
 Yes
 No
 Not Sure/Don't Know
Can the experience of pain make people want to smoke or cause them to smoke more?
 Yes
 No
 Not Sure/Don't Know
Can smoking directly reduce pain in a way that is similar to analgesic pain medications?
 Yes
 No
 Not Sure/Don't Know
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Can smoking help to distract from pain?
 Yes
 No
 Not Sure/Don't Know
Can quitting smoking help to improve pain and physical functioning?
 Yes
 No
 Not Sure/Don't Know
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Cessation Treatment Engagement
Would you like to learn about options for treatment to help you quit smoking?
 No
 Yes
Are you interested in learning more about (Check all that apply)
 Medication/Primary Care
 Quitline
 Behavioral Health
 None of the Above
Do you PLAN TO ENROLL in any treatment in the next 30 days? (Check all that apply)
 Medication/Primary Care
 Quitline
 Behavioral Health
 None of the Above
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Demographics Form
The following questions are about yourself and your life situation. All answers will be kept
confidential.
Gender
 Male
 Female
What is your age?
Date of Birth (mm/dd/yyyy)
What is your marital status? (Choose one)
 Single
 Married
 Separated
 Divorced
 Widowed
With which racial category do you most identify yourself? (Choose one)
 American Indian/Alaska Native
 Asian
 Native Hawaiian or Other Pacific Islander
 Black or African American
 White
 Other ____________________
Are you Hispanic/Latino?
 Yes
 No
What is the highest grade level you have completed? (Choose one)
 Did not graduate high school
 High school graduate
 Some college
 Technical school/Associates degree
 4-year college degree
 Some school beyond 4-year college degree
 Professional degree (e.g. MD, JD, PhD)

57
What is your total household income? (Choose one)
 Under $10,000
 $10,000-$19,999
 $20,000-$29,999
 $30,000-$39,999
 $40,000-$49,999
 $50,000-$59,999
 $60,000-$69,999
 $70,000-$79,999
 $80,000-$89,999
 Over $90,000
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Heaviness of Smoking Index
How soon after you wake up do you smoke your first cigarette?
 Within 5 minutes
 6-30 minutes
 31-60 minutes
 After 60 minutes
How many cigarettes per day do you smoke?
 10 or less
 11 - 20
 21 - 30
 31 or more
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Smoking History Form
How old were you when you started smoking?
For how many years, altogether, have you been a regular/daily smoker?
Over the last week, how many cigarettes did you smoke per day on average?
Have you ever made a serious attempt to quit smoking?
 Yes
 No
How many different times in the past year have you made a serious attempt to quit smoking and
stayed off cigarettes for 24 hours or more?
How many different times in your life have you made a serious attempt to quit smoking and
stayed off cigarettes for 24 hours or more?
What is the longest period of time that you have ever been able to quit smoking? Please select
one answer.
 Hours ____________________
 Days ____________________
 Months ____________________
 Years ____________________
How hard was it for you to quit smoking on your most recent quit attempt?
 Easy
 Slightly Difficult
 Difficult
 Very Difficult
If you quit smoking now, how confident are you that you could go without smoking for
No Confidence

A little
Confidence

Moderately
Confident

Very Confident

Extremely
Confident

One Week
One Month
















One Year
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Do you currently use any other forms of nicotine or tobacco? (Select all that apply)
 I do not use any other forms of nicotine or tobacco
 Cigar or cigarillo
 Smokeless tobacco (e.g., chew, dip, snus, snuff)
 Pipe tobacco
 Hookah
 Electronic Cigarette (e-cig) or Nicotine Vaporizer
 Nicotine gum, patch, or lozenge
 Other (please specify) ____________________
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Stages of Change Algorithm
In the last year, how many times have you quit smoking for at least 24 hours?
Are you seriously thinking of quitting smoking?
 No, not thinking of quitting
 Yes, within the next 6 months
 Yes, within the next 30 days
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Pain and Smoking Inventory
Below are a series of statements about ways that pain may be related to cigarette smoking. Please
rate your level of agreement for each using the following scale:
Not true at
all 0

1

2

Somewhat
true 3

4

5

Extremely
true 6

1. Smoking helps me
cope with my pain.















2. The number of
cigarettes I smoke per
day is often influenced by
my pain.















3. When my pain flares
up I want to have a
cigarette.















4. My pain makes me less
confident that I could
stop smoking for good.















5. Smoking a cigarette
helps me think about
something other than my
pain.















6. My pain would
interfere with any attempt
I make to quit smoking.















7. Feeling pain makes me
want to smoke.















8. My pain prevents me
from trying to quit
smoking.















9. Smoking helps me
cope with the stress and
unhappiness that comes
with pain.
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Graded Chronic Pain Scale
On how many days in the last 180 days (6 months) have you had pain?
How would you rate your pain RIGHT NOW?
 No Pain 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Pain as bad as could be 10
In the last 3 months, how would you rate your WORST pain?
 No Pain 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Pain as bad as could be 10
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In the last 3 months, ON AVERAGE, how would you rate your pain?
 No Pain 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Pain as bad as could be 10
In the last 3 months, how many days did pain keep you from doing DAILY ACTIVITIES (work,
school, homework)?
 None
 1
 2
 3-4
 5-6
 7-10
 11-15
 16-24
 25-60
 61-75
 76-90
In the last 3 months, how much has pain interfered with your DAILY ACTIVITIES?
 No Interference 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Unable to carry on any activities 10
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In the last 3 months, how much has pain interfered with your RECREATIONAL, SOCIAL, &
FAMILY ACTIVITIES?
 No Interference 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Unable to carry on any activities 10
In the last 3 months, how much has pain interfered with your ABILITY TO WORK, including
housework?
 No Interference 0
 1
 2
 3
 4
 5
 6
 7
 8
 9
 Unable to carry on any activities 10
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Pain History
How long have you been experiencing chronic pain?
 Less than 3 months
 4 to 6 months
 7 to 12 months
 Over 1 year to 3 years
 Over 3 years to 5 years
 Over 5 years to 10 years
 Over 10 years
How old were you when you first experienced this type of pain?
How often do you experience this pain?
 It's constant, always there
 At least once a day
 At least once a week
 Not every week, but at least once a month
 Less often
What is the cause of your pain
 Chronic Back Pain
 Chronic Low Back Pain
 Chronic Neck Pain
 Frequent or Severe Headaches
 Cluster Headaches
 Migraines
 Arthritis/Rheumatism
 Fibromyalgia
 Musculoskeletal Pain
 Neuropathic Pain
 Other ____________________
Do you currently have medically unexplained chronic pain? This is defined as pain lasting six
months or longer that is severe enough to either interfere a lot with your normal activities or to
cause a lot of emotional distress and that a doctor cannot find a physical cause to explain.
 Yes
 No
How many doctors have you seen about your pain?
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How satisfied are you with how your doctor is helping you manage your pain?
 Very Satisfied
 Satisfied
 Dissatisfied
 Very dissatisfied
 I have not seen my doctor about pain.
Have you received treatment from a pain specialist or pain treatment program?
 Yes, previously
 Yes, currently
 No
How satisfied are you with how your pain specialist/pain treatment program is helping you
manage your pain?
 Very Satisfied
 Satisfied
 Dissatisfied
 Very Dissatisfied
 I have never received treatment from a pain specialist/pain treatment program.
How often do you take any medication to treat your pain?
 Daily
 Several times a week
 One or two times a week
 One to three times a month
 Rarely
 Never
What types of medication are you taking for your pain (Check all that apply)?
 Over the counter non steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen or
naproxen)
 Over the counter pain relievers such as aspirin or acetaminophen
 Over the counter topical treatments (patch, cream)
 Prescription nonsteroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen or naproxen)
 Prescription pain relievers such as aspirin or acetaminophen
 Prescription topical treatments (patch, cream)
 Prescription opioid/narcotic medication (e.g., OxyContin, Percocet, Vicodin)
 I do not ever take medication for my pain

68
Pain Anxiety Symptoms Scale
Please rate how often you do each of these things when you are in pain using the following scale:
Never
0

1

2

Sometimes 3

4

5

Always
6

1. I think that if my pain gets too severe, it will
never decrease.



 



 



2. When I feel pain I am afraid that something
terrible will happen.



 



 



3. I go immediately to bed when I feel severe pain.



 



 



4. I begin trembling when engaged in an activity
that increases pain.



 



 



5. I can’t think straight when in pain.
6. I will stop any activity as soon as I sense pain
coming on.



 



 





 



 



7. Pain seems to cause my heart to pound or race.



 



 



8. As soon as pain comes on I take medication to
reduce it.



 



 



9. When I feel pain I think I might be seriously ill.



 



 



10. During painful episodes it is difficult for me to
think of anything besides the pain.



 



 



11. I avoid important activities when I hurt.



 



 



12. When I sense pain I feel dizzy or faint.



 



 



13. Pain sensations are terrifying.



 



 



14. When I hurt I think about pain constantly.



 



 



15. Pain makes me nauseous.



 



 



16. When pain comes on strong I think that I might
become paralyzed or more disabled.
17. I find it hard to concentrate when I hurt.



 



 





 



 



18. I find it difficult to calm my body down after
periods of pain.



 



 



19. I worry when I am in pain.



 



 



20. I try to avoid activities that cause pain.
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Prescription Opioid Misuse Index
Please answer the following questions regarding your use of prescription analgesic/opioid
medications only.
Do you ever use MORE of your medication, that is, take a higher dosage, than is prescribed for
you?
 Yes
 No
Do you ever use your medication MORE OFTEN, that is, shorten the time between dosages, than
is prescribed for you?
 Yes
 No
Do you ever need early refills for your pain medication?
 Yes
 No
Do you ever feel high or get a buzz after using your pain medication?
 Yes
 No
Do you ever take your pain medication because you are upset, using the medication to relieve or
cope with problems other than pain?
 Yes
 No
Have you ever gone to multiple physicians including emergency doctors, seeking more of your
pain medication?
 Yes
 No
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Patient Health Questionnaire-4
Over the past 2 weeks have you been bothered by any of the following problems?
0

1

2

3

















Little interest or
pleasure in doing
things.









Feeling down,
depressed, or
hopeless.









Feeling nervous,
anxious, or on
edge.
Not being able to
stop or control
worrying.
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Alcohol Use Disorders Identification Test-C
Think about your drinking over the past year. Please select the response that represents the best
answer for you. One standard drink is equal to: 12 Oz Beer or Wine Cooler 5 Oz Glass of
Wine 1.5 Oz Distilled Spirits
How often do you have a drink containing alcohol?
 Never
 Monthly
 2-4 times a month
 2-3 times a week
 4 or more times a week
How many drinks containing alcohol do you have on a typical day when you are drinking?
 0, I do not drink alcohol
 1 or 2
 3 or 4
 5 or 6
 7 to 9
 10 or more
How often do you have six or more drinks on one occasion?
 Never
 Less than Monthly
 Montly
 Weekly
 Daily or Almost Daily

72
Previous Smoking Cessation Treatment
Have you ever received services to help you quit smoking?
 No
 Yes, I received counseling or therapy
 Yes, I received medication
 Yes, I called the Quitline
 Yes, I talked to my doctor
 Yes, I attended the VA QuitSmart Program
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Client Satisfaction Questionnaire
Please tell us about the services you have received to help you quit smoking. We are interested in
your honest opinions, whether they are positive or negative. Please answer all of the questions.
We also welcome your comments and suggestions.
How would you rate the quality of service you received?
 Poor
 Fair
 Good
 Excellent
Did you get the kind of service you wanted?
 No, definitely not
 No, not really
 Yes, generally
 Yes, definitely
To what extent did the services meet your needs?
 None of my needs have been met
 Only a few of my needs have been met
 Most of my needs have been met
 Almost all of my needs have been met
If a friend were in need of similar help, would you recommend the services to him/her?
 No, definitely not
 No, I don't think so
 Yes, I think so
 Yes, definitely
How satisfied are you with the amount of help you received?
 Very Dissatisfied
 Mildly Dissatisfied
 Mildly Satisfied
 Very Satisfied
Have the services you received helped you to deal more effectively with your problems?
 No, they seemed to make them worse
 No, they didn't really help
 Yes, they helped somewhat
 Yes, they helped a great deal
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In an overall general sense, how satisfied are you with the services you received?
 Very Dissatisfied
 Mildly Dissatisfied
 Mildly Satisfied
 Very Satisfied
If you were to seek help again, would you use these services again?
 No, definitely not
 No, I don't think so
 Yes, I think so
 Yes, definitely
Write additional comments below

On a scale from 1 to 5, rate how helpful you felt the handout was?
 Not at all helpful 1
 2
 3
 4
 Extremely helpful 5
What parts of the handout did you like best?
What parts of the handout did you not like?
On a scale from 1 to 5, rate how understandable you felt the handout was?
 Not at all understandable 1
 2
 3
 4
 Extremely understandable 5
Were there any things you would recommend changing to improve the understandability of the
handout?
Did you feel the meeting with me helped improve your motivation to quit smoking?
 Yes; if so, what aspects of the meeting led you to want to quit? ____________________
 No; if so, why not? ____________________
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On a scale from 1 to 5, rate how satisfied you would be with the format of the discussion if you
were meeting with me at your doctors office after reporting that you are a current smoker?
 Not at all satisfied 1
 2
 3
 4
 Extremely satisfied 5
Would you prefer to have the discussion over the phone instead of in person?
 Yes
 No
Would you prefer to have the discussion over the internet instead of in person?
 Yes
 No
On a scale from 1 to 5, rate how satisfied you would be with the length of time of the discussion?
 Not at all satisfied 1
 2
 3
 4
 Extremely satisfied 5
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Smoking Behavior at One-Month Follow-Up
Do you now smoke cigarettes?
 Not at all
 Some Days
 Every Day
Over the last week, how many cigarettes did you smoke per day on average?
In the past month, have you cut down on your smoking?
 Yes
 No
In the past month, did you quit smoking for at least 24 hours?
 Yes (if yes, how many times?) ____________________
 No
In the past month, did you talk to your doctor about your smoking?
 Yes
 No
In the past month, did you start using a medication to help you quit smoking? (check all that
apply)
 No
 Over the Counter NRT (patch, gum, lozenge)
 Prescription NRT (inhaler, spray)
 Non-NRT Prescription (Chantix/Zyban)
In the past month, did you see a behavioral health provider about your smoking?
 Yes
 No
In the past month, did you call the quitline?
 Yes
 No
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Appendix B
Therapist Guide for the Tailored Intervention
Intervention Component: Personalized Feedback
Rationale
 Feedback about personal risk and impairment is an essential component of brief substance use interventions
(SAMHSA, 2012).
 Personalized feedback is a component of existing evidence-based motivational smoking interventions (e.g.,
Emmons, 2007).
Content
 Smoking History (e.g., tobacco dependence, baseline motivation to quit)
 Pain Complaint (e.g., pain intensity, pain-related disability)
 Pain-Smoking Expectancies (e.g., smoking as a means for pain coping)
Intervention Component: Pain-Smoking Psychoeducation
Rationale
 According to the Health Belief Model, individuals are more likely to change an unhealthy behavior if they
believe that (a) they are susceptible to negative health outcomes, (b) the negative health outcomes will be
severe in nature, and (c) behavior change will be effective in alleviating or reducing these negative
outcomes (Champion & Skinner, 2008).
 Providing smokers with a clear and explicit link between smoking and illness has been shown to increase
motivation to quit (McCaul et al., 2006).
Content
 Reciprocal relations between pain and smoking
 Evidence that smoking may:
o Cause chronic pain
o Increase pain intensity and disability over time
o Interfere with pain treatment
 Smoking in order to cope with pain may lead to worse pain outcomes
 Smokers may experience clinically meaningful improvement in pain severity after quitting
Intervention Component: Develop Discrepancy between Smoking and Desired Pain Outcomes
Rationale
 The Transtheoretical Model (e.g., Prochaska & DiClemente, 1983) predicts that smokers may be motivated
to progress towards behavior change as they come to perceive discrepancy between positive and negative
effects of smoking.
 Developing discrepancy between continued smoking and desired outcomes is a core component of existing
evidence-based motivational smoking interventions (e.g., Emmons, 2007).
 The “5 R’s” (relevance, risk, reward, roadblock, repetition) are recommended by Clinical Practice
Guidelines as a brief motivational smoking intervention (Fiore et al., 2008)
Content
 Elicit desired pain outcomes
 Risks/benefits of smoking with an emphasis on pain outcomes
 “5 R’s”
o Relevance of quitting to pain and desired pain outcomes
o Risks of continued smoking to pain and pain outcomes
o Rewards of quitting for pain and pain outcomes
o Roadblocks to quitting; engagement of smoking cessation treatment to address roadblocks
o Repetition (smoking requires repeated attempts to quit, engagement of smoking cessation
treatment can assist future quit attempts and improve chances of success)
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Appendix C
Psychoeducation Handout for the Tailored Intervention

You might be interested to know …
 Smoking causes chronic pain!
 Smoking makes pain worse over time!
 Smoking can interfere with pain treatment!

Even if pain makes some people want to smoke…
 Smoking to cope with pain has been linked
to worse pain over time!

But… there’s GOOD NEWS!
People who quit smoking have lower
pain and can get back to doing the
things they enjoy!
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Appendix D
Therapist Guide for the Control Intervention
All components of the control intervention are consistent with the US Department of Health and Human Services
Clinical Practice Guidelines (Fiore et al., 2008) recommendations for the 3As (i.e., Ask, Advise, Arrange) brief
smoking intervention.
Intervention Component: Ask
Rationale
 Clinical Practice Guidelines recommends that all smokers be asked about current smoking (Fiore et al.,
2008)
Content
 Assess current smoking behavior
 Assess readiness to quit smoking
Intervention Component: Advise
Rationale
 Clinical Practice Guidelines recommend that all smokers be advised to quit smoking (Fiore et al., 2008)
Content
 Provide advice to quit smoking
Intervention Component: Arrange
Rationale
 Clinical Practice Guidelines recommend that all smokers be who are interested in have follow-up arranged
(Fiore et al., 2008)
Content
 Provide Clearing the Air (National Cancer Institute)
 Offer information about other treatment resources
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Appendix E
Tailored Intervention Fidelity Checklist
1. Did the interventionist provide personalized feedback? (Check all that apply)
___ Smoking History
___ Pain Complaint
___ Pain-Smoking Expectancies

2. Did the interventionist provide psychoeducation about pain-smoking interrelations? (Check all
that apply)
___ Reciprocal Relations between Pain and Smoking
___ Effects of Smoking on Pain
___ Effects of Smoking to Cope with Pain
___ Effects of Quitting Smoking on Pain

3. Did the interventionist develop discrepancy between smoking and desired pain outcomes?
(Check all that apply)
___ Elicit Desired Pain Outcomes
___ Risks/benefits of Smoking
___ 5Rs (relevance, risks, rewards, roadblocks, repetition)
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Appendix F
Control Intervention Fidelity Checklist
1. Did the interventionist ask about smoking? (Check all that apply)
___ Current Smoking Behavior
___ Readiness to quit

2. Did the interventionist provide advice to quit smoking?
___ Yes
___ No

3. Did the interventionist offer assistance/resources for quitting?
___ Yes
___ No
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Appendix G
Smoking Cessation Resources Handout

Interested in quitting smoking?
Services are available to help you quit.
New York State Smokers’ Quitline
 1-866-NY-QUITS (1-866-697-8487)
o Mon-Thurs: 9 a.m. - 9 p.m.
o Fri, Sat and Sun: 9 a.m. - 5 p.m.
 Check them out online at www.nysmokefree.com

Smoking Cessation Medication
 Your doctor can help determine which medication is best for
you.
 Medication options include:
o Over-the-counter nicotine replacement therapy
(patches, gum, lozenges)
o Prescription nicotine replacement therapy (inhaler,
nasal spray)
o Non-nicotine prescription medication (bupropion/Zyban
and varenicline/Chantix).
 Talk to your doctor to learn more about medications for
smoking cessation.

83
References
Aamodt, A. H., Stovner, L. J., Hagen, K., Brathen, G., & Zwart, J. (2006). Headache prevalence
related to smoking and alcohol use. The Head-HUNT Study. European Journal of
Neurology, 13, 1233-1238. doi: 10.1111/j.1468-1331.2006.01492.x
Aigner, C. J., Gritz, E. R., Tamí-Maury, I., Baum, G. P., Arduino, R. C., & Vidrine, D. J. (2017).
The Role of Pain in Quitting among HIV Positive Smokers Enrolled in a Smoking
Cessation Trial. Substance Abuse, 00-00. doi: 10.1080/08897077.2017.1291466
Aimer, P., Stamp, L., Stebbings, S., Valentino, N., Cameron, V., & Treharne, G. J. (2015).
Identifying Barriers to Smoking Cessation in Rheumatoid Arthritis. Arthritis Care and
Research, 67, 607-615. doi: 10.1002/acr.22503
Amin, S., Niu, J., Guermazi, A., Grigoryan, M., Hunter, D. J., Clancy, M., . . . Felson, D. T.
(2007). Cigarette smoking and the risk for cartilage loss and knee pain in men with knee
osteoarthritis. Annals of the Rheumatic Diseases, 66, 18-22. doi:
10.1136/ard.2006.056697
Arean, P. A., & Alvidrez, J. (2002). Ethical considerations in psychotherapy effectiveness
research: Choosing the comparison group. Ethics and Behavior, 12, 63-73. doi:
10.1207/S15327019EB1201_4
Augustson, E., & Marcus, S. (2004). Use of the current population survey to characterize
subpopulations of continued smokers: a national perspective on the "hardcore" smoker
phenomenon. Nicotine & Tobacco Research, 6, 621-629. doi:
10.1080/14622200410001727876

84
Babb, S. D., Malarcher, A. M., Schauer, G. L., Asman, K., & Jamal, A. (2017). Quitting smoking
among adults -- United States, 2000-2015. MMWR: Morbidity and Mortality Weekly
Report, 65, 1457-1464. doi: 10.15585/mmwr.mm6552a1
Baker, T. B., Collins, L. M., Mermelstein, R., Piper, M. E., Schlam, T. R., Cook, J. W., . . .
Fiore, M. C. (2016). Enhancing the effectiveness of smoking treatment research:
conceptual bases and progress. Addiction, 111, 107-116. doi: 10.1111/add.13154
Baker, T. B., Mermelstein, R., Collins, L. M., Piper, M. E., Jorenby, D. E., Smith, S. S., . . .
Fiore, M. C. (2011). New Methods for Tobacco Dependence Treatment Research. Annals
of Behavioral Medicine, 41, 192-207. doi: 10.1007/s12160-010-9252-y
Behrend, C., Prasarn, M., Coyne, E., Horodyski, M., Wright, J., & Rechtine, G. R. (2012).
Smoking Cessation Related to Improved Patient-Reported Pain Scores Following Spinal
Care. Journal of Bone and Joint Surgery (American Volume), 94, 2161-2166. doi:
10.2106/JBJS.K.01598
Benowitz, N. L., Jacob, P., K., A., Jarvis, M. J., Hall, S., LeHouezec, J., . . . Hurt, R. D. (2002).
Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4,
149-159. doi: 10.1080/14622200210123581
Biener, L., & Abrams, D. B. (1991). The Contemplation Ladder: validation of a measure of
readiness to consider smoking cessation. Health Psychology, 10, 360-365. doi:
10.1037//0278-6133.10.5.360
Borland, R., Yong, H. H., O'Connor, R. J., Hyland, A., & Thompson, M. E. (2010). The
reliability and predictive validity of the Heaviness of Smoking Index and its two
components: findings from the International Tobacco Control Four Country study.
Nicotine & Tobacco Research, 12 Suppl, S45-50. doi: 10.1093/ntr/ntq038

85
Borrelli, B. (2010). Smoking cessation: next steps for special populations research and
innovative treatments. Journal of Consulting and Clinical Psychology, 78, 1-12. doi:
10.1037/a0018327
Boudreaux, E. D., Sullivan, A., Abar, B., Bernstein, S. L., Ginde, A. A., & Camargo, C. A., Jr.
(2012). Motivation rulers for smoking cessation: a prospective observational examination
of construct and predictive validity. Addiction Science & Clinical Practice, 7, 8. doi:
10.1186/1940-0640-7-8
Brown, R. A., Lejuez, C. W., Kahler, C. W., & Strong, D. R. (2002). Distress tolerance and
duration of past smoking cessation attempts. Journal of Abnormal Psychology, 111, 180185. doi: 10.1037//0021-843X.111.1.180
Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT
alcohol consumption questions (AUDIT-C): an effective brief screening test for problem
drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use
Disorders Identification Test. Archives of Internal Medicine, 158, 1789-1795.
Cahill, K., Lancaster, T., & Green, N. (2010). Stage-based interventions for smoking cessation.
Cochrane Database Syst Rev, CD004492. doi: 10.1002/14651858.CD004492.pub4
CDC. (2011). Quitting Smoking Among Adults --- United States, 2001--2010. Morbidity and
Mortality Weekly Report, 60, 1513-1519.
Chaiton, M. O., Cohen, J. E., McDonald, P. W., & Bondy, S. J. (2007). The Heaviness of
Smoking Index as a predictor of smoking cessation in Canada. Addictive Behaviors, 32,
1031-1042.

86
Champion, V. L., & Skinner, C. S. (2008). The Health Belief Model. In K. Glanz, B. K. Rimer &
K. Viswanath (Eds.), Health Behavior and Health Education: Theory, Research, and
Practice (4th ed., pp. 45-65). San Fransisco: CA: Jossey-Bass, a Wiley Imprint.
Cheema, J. R. (2014). Some general guidelines for choosing missing data handling methods in
educational research. Journal of Modern Applied Statistical Methods, 13, 55-57.
Cropsey, K. L., Eldridge, G. D., Weaver, M. F., Villalobos, G. C., & Stitzer, M. L. (2006).
Expired carbon monoxide levels in self-reported smokers and nonsmokers in prison.
Nicotine & Tobacco Research, 8, 653-659. doi: 10.1080/14622200600789684
Cunningham, J. A. (2007). Internet-based interventions for alcohol, tobacco and other substances
of abuse. In P. M. Miller & D. Kavanagh (Eds.), Translation of addictions science into
practice (pp. 399-416). New York, NY: Elsevier Science.
DHHS. (2004). The Health Consequences of Smoking: A Report of the Surgeon General.
Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease
Control and Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
DHHS. (2008). Quick guide to health literacy: Fact sheets, strategies, resources. Washington,
DC: Retrieved from https://health.gov/communication/literacy/quickguide/.
DHHS. (2014). The Health Consequences of Smoking - 50 Years of Progress: A Report of the
Surgeon General. Atlanta: GA: U.S. Department of Health and Human Services, Center
for Disease COntrol and Prevention, National Center for Chronic Disease Prevention and
Health Promotion, Office on Smoking and Health.

87
Dhingra, L. K., Homel, P., Grossman, B., Chen, J., Scharaga, E., Calamita, S., . . . Portenoy, R.
(2013). Ecological Momentary Assessment of Smoking Behavior in Persistent Pain
Patients. Clinical Journal of Pain, 30, 205-213. doi: 10.1097/AJP.0b013e31829821c7
DiClemente, C. C., Prochaska, J. O., Fairhurst, S. K., Velicer, W. F., Velasquez, M. M., & Rossi,
J. S. (1991). The process of smoking cessation: an analysis of precontemplation,
contemplation, and preparation stages of change. Journal of Consulting and Clinical
Psychology, 59, 295-304. doi: 10.1037//0022-006X.59.2.295
Ditre, J. W., & Brandon, T. H. (2008). Pain as a motivator of smoking: Effects of pain induction
on smoking urge and behavior. Journal of Abnormal Psychology, 117, 467-472. doi:
10.1037/0021-843X.117.2.467
Ditre, J. W., Brandon, T. H., Zale, E. L., & Meagher, M. M. (2011). Pain, nicotine, and smoking:
Research findings and mechanistic considerations. Psychological Bulletin, 137, 10651093. doi: 10.1037/a0025544
Ditre, J. W., Heckman, B. W., Butts, E. A., & Brandon, T. H. (2010). Effects of expectancies and
coping on pain-induced motivation to smoke. Journal of Abnormal Psychology, 119, 524533. doi: 10.1037/a0019568
Ditre, J. W., Kosiba, J. D., Zale, E. L., Zvolensky, M. J., & Maisto, S. A. (2016). Chronic pain
status, nicotine withdrawal, and expectancies for smoking cessation among lighter
smokers. Annals of Behavioral Medicine, 50, 427-435. doi: 10.1007/s12160-016-9769-9
Ditre, J. W., Langdon, K. J., Kosiba, J. D., Zale, E. L., & Zvolensky, M. J. (2015). Relations
between pain-related anxiety, tobacco dependence, and barriers to quitting among a
community-based sample of daily smokers. Addictive Behaviors, 42, 130-135. doi:
10.1016/j.addbeh.2014.11.032

88
Ditre, J. W., Zale, E. L., Heckman, B. W., & Hendricks, P. S. (2016). A measure of perceived
pain and tobacco smoking interrelations: pilot validation of the pain and smoking
inventory. Cognitive Behaviour Therapy, 1-13. doi: 10.1080/16506073.2016.1256347
Ditre, J. W., Zale, E. L., Kosiba, J. D., & Zvolensky, M. J. (2013). A pilot study of pain-related
anxiety and smoking-dependence motives among persons with chronic pain.
Experimental and Clinical Psychopharmacology, 21, 443-449. doi: 10.1037/a0034174
Drake, R. E., & Mueser, K. T. (2000). Psychosocial approaches to dual diagnosis. Schizophrenia
Bulletin, 26, 105-118. doi: 10.1093/oxfordjournals.schbul.a033429
Eccleston, C., & Crombez, G. (1999). Pain demands attention: a cognitive-affective model of the
interruptive function of pain. Psychological Bulletin, 125, 356-366.
Emmons, K. M. (2007). Increasing Motivation to Stop Smoking. In D. B. Abrams, R. Niaura, R.
A. Brown, K. M. Emmons, M. G. Goldstein & P. M. Monti (Eds.), The Tobacco
Dependence Treatment Handbook: A Guide to Best Practices (pp. 73-100). New York:
The Guildford Press.
Evans, D. E., Sutton, S. K., Oliver, J. A., & Drobes, D. J. (2015). Cortical activity differs during
nicotine deprivation versus satiation in heavy smokers. Psychopharmacology, 232, 18791885. doi: 10.1007/s00213-014-3821-x
Fagerstrom, K. (2012). Determinants of tobacco use and renaming the FTND to the Fagerstrom
Test for Cigarette Dependence. Nicotine & Tobacco Research, 14, 75-78. doi:
10.1093/ntr/ntr137
Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., & Dorfman,
S. F. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice

89
Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public
Health Service. May 2008.
Fishbain, D. A., Lewis, J. E., Cutler, R., Cole, B., Steele Rosomoff, R., & Rosomoff, H. L.
(2008). Does smoking status affect multidisciplinary pain facility treatment outcome?
Pain Medicine, 9, 1081-1090. doi: 10.1111/j.1526-4637.2007.00306.x
Funderburk, J. S., Sugarman, D. E., Maisto, S. A., Ouimette, P., Schohn, M., Lantinga, L., . . .
Strutynski, K. (2010). The description and evaluation of the implementation of an
integrated healthcare model. Families, Systems, & Health, 28, 146-160. doi:
10.1037/a0020223
Garson, G. D. (2015). Missing values analysis & data imputation. Asheboro, NC: Statistical
Publishing Associates
Glassman, S. D., Dimar, J. R. I., Burkus, K., Hardacker, J. W., Pryor, P. W., Boden, S. D., &
Carreon, L. Y. (2007). The Efficacy of rhBMP-2 for Posterolateral Lumbar Fusion in
Smokers. Spine, 32, 1693-1698. doi: 10.1097/BRS.0b013e318074c366
Goesling, J., Brummett, C. M., & Hassett, A. L. (2012). Cigarette smoking and pain: depressive
symptoms mediate smoking-related pain symptoms. Pain, 153, 1749-1754. doi:
10.1016/j.pain.2012.05.014
Gupta, S. K. (2011). Intention-to-treat concept: A review. Perspectives in Clinical Research, 2,
109-112. doi: 10.4103/2229-3485.83221
Hahn, E. J., Rayens, M. K., Kirsh, K. L., & Passik, S. D. (2006). Brief report: Pain and readiness
to quit smoking cigarettes. Nicotine & Tobacco Research, 8, 473-480. doi:
10.1080/14622200600670355

90
Hall, S. M., Havassy, B. E., & Wasserman, D. A. (1990). Commitment to abstinence and acute
stress in relapse to alcohol, opiates, and nicotine. Journal of Consulting and Clinical
Psychology, 58, 175-181.
Harty, L. C., & Veale, D. J. (2010). Irish smokers with rheumatoid arthritis suffer more than their
nonsmoking counterparts. Journal of Rheumatology, 37, 1062; author reply 1063. doi:
10.3899/jrheum.091403
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., Rickert, W., & Robinson, J. (1989).
Measuring the heaviness of smoking: using self-reported time to the first cigarette of the
day and number of cigarettes smoked per day. British Journal of Addiction, 84, 791-799.
Herzog, T. A., & Blagg, C. O. (2007). Are most precontemplators contemplating smoking
cessation? Assessing the validity of the stages of change. Health Psychology, 26, 222231. doi: 10.1037/0278-6133.26.2.222
Hooten, W. M., Shi, Y., Gazelka, H. M., & Warner, D. O. (2011). The effects of depression and
smoking on pain severity and opioid use in patients with chronic pain. Pain, 152, 223229. doi: 10.1016/j.pain.2010.10.045
Hooten, W. M., Townsend, C. O., Bruce, B. K., Schmidt, J. E., Kerkvliet, J. L., Patten, C. A., &
Warner, D. O. (2009). Effects of smoking status on immediate treatment outcomes of
multidisciplinary pain rehabilitation. Pain Medicine, 10, 347-355. doi: 10.1111/j.15264637.2008.00494.x
Hooten, W. M., Townsend, C. O., Bruce, B. K., & Warner, D. O. (2009). The effects of smoking
status on opioid tapering among patients with chronic pain. Anesthesia and Analgesia,
108, 308-315. doi: 10.1213/ane.0b013e31818c7b99

91
Hooten, W. M., Townsend, C. O., Hays, J. T., Ebnet, K. L., Gauvin, T. R., Gehin, J. M., . . .
Warner, D. O. (2014). A cognitive behavioral smoking abstinence intervention for adults
with chronic pain: A randomized controlled pilot trial. Addictive Behaviors, 39, 593-599.
doi: 10.1016/j.addbeh.2013.11.010
Hooten, W. M., Vickers, K. S., Shi, Y., Ebnet, K. L., Townsend, C. O., Patten, C. A., & Warner,
D. O. (2011). Smoking cessation and chronic pain: patient and pain medicine physician
attitudes. Pain Practice, 11, 552-563. doi: 10.1111/j.1533-2500.2011.00462.x
Hughes, J. R., & Brandon, T. H. (2003). A softer view of hardening. Nicotine & Tobacco
Research, 5, 961-962. doi: 10.1080/14622200310001615330
Hung, J., Lin, C. H., Wang, J. D., & Chan, C. C. (2006). Exhaled carbon monoxide level as an
indicator of cigarette consumption in a workplace cessation program in Taiwan. Journal
of the Formosan Medical Association, 105, 210-213. doi: 10.1016/S09296646(09)60307-7
IOM. (2011). Relieving Pain in America: A Blueprint for Transforming Prevention, Care,
Education, and Research. Washington, DC: The National Academies Press
Irvin, J. E., & Brandon, T. H. (2000). The increasing recalcitrance of smokers in clinical trials.
Nicotine & Tobacco Research, 2, 79-84. doi: 10.1080/14622200050011330
Jamal, A., King, B. A., Neff, L. J., Whitmill, J., Babb, S. D., & Graffunder, C. M. (2016).
Current cigarette smoking among adults -- United States, 2005 - 2015. MMWR CDC
Surveillance Summaries, 65, 1205-1211. doi: 10.15585/mmwr.mm6544a2
James, L. C., & Folen, R. A. (Eds.). (2005). The primary care consultant: The next frontier for
psychologists in hospitals and clinics. Washington, DC, US: American Psychological
Association.

92
Jamison, R. N., Stetson, B. A., & Parris, W. C. (1991). The relationship between cigarette
smoking and chronic low back pain. Addictive Behaviors, 16, 103-110. doi:
10.1016/0306-4603(91)90002-Y
Javors, M. A., Hatch, J. P., & Lamb, R. J. (2005). Cut-off levels for breath carbon monoxide as a
marker for cigarette smoking. Addiction, 100, 159-167. doi: 10.1111/j.13600443.2004.00957.x
Kaye, A. D., Prabhakar, A. P., Fitzmaurice, M. E., & Kaye, R. J. (2012). Smoking cessation in
pain patients. The Ochsner Journal, 12, 17-20.
Kessler, R. C., Berglund, P., Chiu, W. T., Demler, O., Heeringa, S., Hiripi, E., . . . Zheng, H.
(2004). The US National Comorbidity Survey Replication (NCS-R): design and field
procedures. International Journal of Methods in Psychiatric Research, 13, 69-92. doi:
10.1002/mpr.167
Knisely, J. S., Wunsch, M. J., Cropsey, K. L., & Campbell, E. D. (2008). Prescription Opioid
Misuse Index: a brief questionnaire to assess misuse. Journal of Substance Abuse
Treatment, 35, 380-386. doi: 10.1016/j.jsat.2008.02.001
Krebs, E. E., Carey, T. S., & Weinberger, M. (2007). Accuracy of the pain numeric rating scale
as a screening test in primary care. Journal of General Internal Medicine, 22, 1453-1458.
doi: 10.1007/s11606-007-0321-2
Kroenke, K., Spitzer, R. L., Williams, J. B., & Lowe, B. (2009). An ultra-brief screening scale
for anxiety and depression: the PHQ-4. Psychosomatics, 50, 613-621. doi:
10.1176/appi.psy.50.6.613

93
Kwok, T. C., Taggar, J., Cooper, S., Lewis, S., & Coleman, T. (2014). Nicotine dependence and
biochemical exposure measures in the second trimester of pregnancy. Nicotine &
Tobacco Research, 16, 145-154. doi: 10.1093/ntr/ntt127
Lancaster, T., Stead, L., Silagy, C., & Sowden, A. (2000). Regular review: Effectiveness of
interventions to help people stop smoking: findings from the Cochrane Library. BMJ,
321, 355. doi: 10.1136/bmj.321.7257.355
LaRowe, L. R., Langdon, K. J., Zvolensky, M. J., Zale, E. L., & Ditre, J. W. (in press). PainRelated Anxiety as a Predictor of Early Lapse and Relapse to Cigarette Smoking.
Experimental and Clinical Psychopharmacology.
Larsen, D. L., Attkisson, C. C., Hargreaves, W. A., & Nguyen, T. D. (1979). Assessment of
client/patient satisfaction: development of a general scale. Evaluation and Program
Planning, 2, 197-207.
Lawson, P. J., & Flocke, S. A. (2009). Teachable moments for health behavior change: a concept
analysis. Patient Education and Counseling, 76, 25-30. doi: 10.1016/j.pec.2008.11.002
Lee, S. S., Kim, S. H., Nah, S. S., Lee, J. H., Lee, Y. A., Hong, S. J., . . . Kim, S. K. (2010).
Smoking habits influence pain and functional and psychiatric features in fibromyalgia.
Joint, Bone, Spine: Revue du Rhumatisme, 78, 259-265. doi:
10.1016/j.jbspin.2010.07.018
Lichtenstein, E., & Hollis, J. (1992). Patient referral to a smoking cessation program: Who
follows through? The Journal of Family Practice, 34, 739-744.
McCaul, K. D., Hockemeyer, J. R., Johnson, R. J., Zetocha, K., Quinlan, K., & Glasgow, R. E.
(2006). Motivation to quit using cigarettes: A review. Addictive Behaviors, 31, 42-56.
doi: 10.1016/j.addbeh.2005.04.004

94
McCracken, L. M., & Dhingra, L. (2002). A short version of the Pain Anxiety Symptoms Scale
(PASS-20): preliminary development and validity. Pain Research and Management, 7,
45-50.
Michna, E., Ross, E. L., Hynes, W. L., Nedeljkovic, S. S., Soumekh, S., Janfaza, D., . . .
Jamison, R. N. (2004). Predicting aberrant drug behavior in patients treated for chronic
pain: importance of abuse history. Journal of Pain and Symptom Management, 28, 250258. doi: 10.1016/j.jpainsymman.2004.04.007
Mohr, D. C., Spring, B., Freedland, K. E., Beckner, V., Arean, P., Hollon, S. D., . . . Kaplan, R.
(2009). The Selection and Design of Control Conditions for Randomized Controlled
Trials of Psychological Interventions. Psychotherapy and Psychosomatics, 78, 275-284.
doi: 10.1159/000228248
Nakajima, M., & al'Absi, M. (2011). Enhanced pain perception prior to smoking cessation is
associated with early relapse. Biological Psychology, 88, 141-146. doi:
10.1016/j.biopsycho.2011.07.006
Nezami, E., Sussman, S., & Pentz, M. A. (2003). Motivation in Tobacco Use Cessation
Research. Substance Use and Misuse, 38, 25-50. doi: 10.1081/JA-120016564
Niaura, R., & Shadel, W. G. (2007). Assessment to inform smoking cessation treatment. In D. B.
Abrams, R. Niaura, R. A. Brown, K. M. Emmons, M. G. Goldstein & P. M. Monti (Eds.),
The Tobacco Dependence Treatment Handbook: A Guide to Best Practices (pp. 27-72).
New York, NY: The Guilford Press.
Orhurhu, V. J., Pittelkow, T. P., & Hooten, W. M. (2015). Prevalence of smoking in adults with
chronic pain. Tobacco Induced Diseases, 13, 17. doi: 10.1186/s12971-015-0042-y

95
Patel, N., Talwar, A., Reichert, V. C., Brady, T., Jain, M., & Kaplan, M. H. (2006). Tobacco and
HIV. Clinics in Occupational and Environmental Medicine, 5, 193-207, xi.
Patterson, A. L., Gritzner, S., Resnick, M. P., Dobscha, S. K., Turk, D. C., & Morasco, B. J.
(2012). Smoking cigarettes as a coping strategy for chronic pain is associated with greater
pain intensity and poorer pain-related function. Journal of Pain, 13, 285-292. doi:
10.1016/j.jpain.2011.11.008
Perkins, K. A., Conklin, C. A., & Levine, M. D. (2008). Cognitive-Behavioral Therapy for
Smoking Cessation: A Practical Guidebook to the Most Effective Treatments. New York,
NY: Routledge.
Piper, M. E., & Curtin, J. J. (2006). Tobacco withdrawal and negative affect: an analysis of
initial emotional response intensity and voluntary emotion regulation. Journal of
Abnormal Psychology, 115, 96-102. doi: 10.1037/0021-843X.115.1.96
Pisinger, C., Jørgensen, M. M., Møller, N. E., Døssing, M., & Jørgensen, T. (2010). A cluster
randomized trial in general practice with referral to a group-based or an internet-based
smoking cessation programme. Journal of Public Health, 32, 62-70. doi:
10.1093/pubmed/fdp072
Prochaska, J. O., & DiClemente, C. C. (1983). Stages and processes of self-change of smoking:
toward an integrative model of change. Journal of Consulting and Clinical Psychology,
51, 390-395.
Prochaska, J. O., Redding, C. A., & Evers, K. E. (2008). The Transtheoretical Model and Stages
of Change. In K. Glanz, B. K. Rimer & K. Viswanath (Eds.), Health Behavior and
Health Education: Theory, Research, and Practice (4th ed., pp. 97-121). San Fransisco:
CA: Jossey-Bass, a Wiley Imprint.

96
Raiff, B. R., Faix, C., Turturici, M., & Dallery, J. (2010). Breath carbon monoxide output is
affected by speed of emptying the lungs: implications for laboratory and smoking
cessation research. Nicotine & Tobacco Research, 12, 834-838. doi: 10.1093/ntr/ntq090
Riper, H., van Straten, A., Keuken, M., Smit, F., Schippers, G., & Cuijpers, P. (2009). Curbing
problem drinking with personalized-feedback interventions: a meta-analysis. American
Journal of Preventive Medicine, 36, 247-255. doi: 10.1016/j.amepre.2008.10.016
SAMHSA. (2012). Brief interventions and brief therapies for substance abuse. Treatment
Improvement Protocol (TIP) Series, No. 34. HHS Publication No. (SMA) 12-3952.
Rockville, MD: Substance Abuse and Mental Health Services Administration.
SAMHSA. (2013). Motivational Enhancement Therapy Retrieved 1/30/2014, from
http://www.nrepp.samhsa.gov/ViewIntervention.aspx?id=347
Seligman, H. K., Wang, F. F., Palacios, J. L., Wilson, C. C., Daher, C., Piette, J. D., &
Schillinger, D. (2005). Physician notification of their diabetes patients' limited health
literacy. A randomized, controlled trial. Journal of General Internal Medicine, 20, 10011007. doi: 10.1111/j.1525-1497.2005.00189.x
Shiri, R., Karppinen, J., Leino-Arjas, P., Solovieva, S., & Viikari-Juntura, E. (2010). The
association between smoking and low back pain: a meta-analysis. American Journal of
Medicine, 123, 87 e87-35. doi: 10.1016/j.amjmed.2009.05.028
Tai-Seale, M., McGuire, T. G., & Zhang, W. (2007). Time allocation in primary care office
visits. Health Services Research, 42, 1871-1894. doi: 10.1111/j.1475-6773.2006.00689.x
Toblin, R. L., Mack, K. A., Perveen, G., & Paulozzi, L. J. (2011). A population-based survey of
chronic pain and its treatment with prescription drugs. Pain, 152, 1249-1255. doi:
10.1016/j.pain.2010.12.036

97
USDHHS. (2010). Ending the tobacco epidemic: A tobacco control strategic action plan for the
U.S. Department of Health and Human Services. Washington, DC: Office of the
Assistant Secretary for Health
Von Korff, M. (2011). Assessment of chronic pain in epidemiological and health services
research. In D. C. Turk & R. Melzack (Eds.), Handbook of Pain Assessment: Third
Edition. New York, NY: The Guilford Press.
Waldie, K. E., McGee, R., Reeder, A. I., & Poulton, R. (2008). Associations between frequent
headaches, persistent smoking, and attempts to quit. Headache, 48, 545-552. doi:
10.1111/j.1526-4610.2007.01037.x
Weingarten, T. N., Moeschler, S. M., Ptaszynski, A. E., Hooten, W. M., Beebe, T. J., & Warner,
D. O. (2008). An assessment of the association between smoking status, pain intensity,
and functional interference in patients with chronic pain. Pain physician, 11, 643-653.
Weingarten, T. N., Podduturu, V. R., Hooten, W. M., Thompson, J. M., Luedtke, C. A., & Oh, T.
H. (2009). Impact of tobacco use in patients presenting to a multidisciplinary outpatient
treatment program for fibromyalgia. Clinical Journal of Pain, 25, 39-43. doi:
10.1097/AJP.0b013e31817d105e
Winn, D. M. (2001). Tobacco use and oral disease. Journal of Dental Education, 65, 306-312.
Zale, E. L., Ditre, J. W., Dorfman, M. L., Heckman, B. W., & Brandon, T. H. (2014). Smokers in
Pain Report Lower Confidence and Greater Difficulty Quitting. Nicotine & Tobacco
Research, 16, 1272-1276.
Zale, E. L., Maisto, S. A., & Ditre, J. W. (2016). Anxiety and Depression in Bidirectional
Relations Between Pain and Smoking: Implications for Smoking Cessation. Behavior
Modification, 40, 7-28. doi: 10.1177/0145445515610744

98
Zvolensky, M. J., Lejuez, C. W., Kahler, C. W., & Brown, R. A. (2003). Integrating an
interoceptive exposure-based smoking cessation program into the cognitive-behavioral
treatment of panic disorder: Theoretical relevance and case demonstration. Cognitive and
Behavioral Practice, 10, 347-357. doi: 10.1016/S1077-7229(03)80052-4

99
VITA
NAME OF AUTHOR: Emily L. Zale
CONTACT INFORMATION:
430 Huntington Hall
Syracuse, NY 13244
GRADUATE AND UNDERGRADUATE SCHOOLS ATTENDED:
Syracuse University, Syracuse, NY
Texas A&M University, College Station, TX
University of Rochester, Rochester, NY
DEGREES AWARDED:
Master of Science, 2012, Texas A&M University
Bachelor of Arts in Psychology and Anthropology, 2007, University of Rochester

